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Abstract 
With the recent progress in nanoscience and great deal of understanding in 
molecular biology, it is now possible to combine genetic tools with synthetic nano- 
constructs for improved biotechnology applications. Viruses with its inherent 
nanosize architecture, genetic flexibility, stability to harsh conditions, circulatory 
behavior and targeting ability, in combination with nano science, are currently an 
excellent source for designing nano based therapeutics for cancer diagnosis and 
treatment. Here, we integrate phage display technology (PDT) with nanotechnology 
to synthesize novel nano-conjguates for potential biomedical applications.   
The first part of this dissertation is focused on the identification and 
characterization of novel SKBR-3 breast cancer cell targeting/internalizing ligands 
using landscape phage libraries. We used several computational methods and 
biochemical approaches to characterize the specificity, affinity and selectivity of the 
screened bacteriophage against target SKBR-3 breast cancer cells. In order to 
understand the mechanism of entry, we investigated the actin dynamics by using live 
cell and fluorescence imaging during selected phage internalization into target 
SKBR-3 cells. In conclusion, we demonstrate that phage harboring VSSTQDFP and 
DGSIPWST peptides could selectively internalize into SKBR-3 cells with high 
affinity and show rapid involvement of membrane ruffling and rearrangements of 
actin cytoskeleton during phage entry.  
The second part of this dissertation is focused on the isolation of major coat 
proteins, pVIII from screened bacteriophage, its conjugation on functionalized gold 
xxi 
 
nanorod using appropriate chemistry and its multipurpose applications.  The 
successful conjugation of coat proteins on functionalized gold nanorods was verified 
by using spectroscopic and microscopic techniques. In conclusion, we demonstrate 
that the resulting protein/peptide- nanoconjugates can be used for imaging and 
selective photo thermal destruction of SKBR-3 breast cancer cells upon exposure to 
near-infrared (NIR) light. In order, to gain insight into the mechanism and understand 
the key cellular processes involved following the treatment of these nanoconjugates, 
we used illumina microarray technique to explore the molecular interactions with in 
our model SKBR-3 breast cancer cells. We identified 76 genes to be up regulated and 
26 genes are down regulated following the treatment of protein nanoconjugates. Our 
recent preliminary animal studies in SKBR-3 tumor model (nude mice) shows that 
these protein-nanoconjugates are feasible for in vivo applications. However, more in 
vivo experiments are under investigations before its clinical significance is realized. 
The third part of this dissertation is focused on the assembly of coat proteins 
on functionalized carbon nanotubes and other biomedical applications of engineered 
bacteriophage in nanoscience. Using various spectroscopic and microscopic studies, 
we demonstrate phage proteins assembled on carbon nanotubes can be used for 
imaging purpose, and SKBR-3 specific bacteriophage can be used as a template for 
conjugation of photosensitizer, pyropheophorbid-a for targeted photo dynamic 
therapy. We also demonstrate filamentous bacteriophage displayed with eight 
glutamic acid residues [E8] on the N-terminus of major coat protein using phage 
display can be used as a template to assemble liposomes and form phage-liposome 
complex for targeted drug delivery.  
1 
 
Chapter1: Introduction 
1.1. Bacteriophage libraries and their applications 
1.1.1. Structure and Biology of Filamentous bacteriophage 
Bacteriophages are a group of viruses that infect bacteria.  Filamentous bacteriophage is a 
flexible rod like virus (with ~0.9 μm length and ~6.5 nm width) that specifically infects a 
wide variety of gram negative bacteria, including Escherichia coli, Xanthomonas, 
Pseudomonas and Salmonella  [1]. Previous X-ray diffraction studies identified two  
classes of filamentous viruses: Class I, includes M13, fd, f1 and Ike, and Class II, 
includes Pf1 and Xf  [2]. Here, the discussion is restricted to Class I viruses (M13 and fd 
specifically) as they were well characterized and were used in this dissertation research. 
Class I viruses are grouped under Ff class because of their host cell entry through F 
conjugative pilus on the surface of male E. coli cells  [3]. The Ff phage genome encodes 
a total of 11 proteins  including five structural proteins (pVIII, pIII, pVI, pVII, and pIX), 
and six non structural proteins (pI, pXI, pIV, pII, pX, and pV)  [4]. The intact Ff viruses 
posses single stranded (ss)-DNA as its genome surrounded by major and minor coat 
proteins. Figure 1-1A shows the schematic organization and the relative positions of all 
structural proteins on filamentous bacteriophage  [5] and Figure 1-1B shows the electron 
micrograph of  filamentous bacteriophage  [6]. In M13 bacteriophage, Gene VIII codes 
for approximately 2700 copies of major coat proteins pVIII (50 amino acids and 
Molecular weight 5253) which constitutes the major fraction (~85%) of the virus 
2 
 
particles. It forms a thin flexible cylinder around the single-stranded DNA. Each pVIII 
subunit is α-helical protein with three distinct domains:  [7] acidic N-terminus domain 
(residues 1-20) exposed to the solvent; basic C-terminal domain (residues 40-50) with 
four lysine residues responsible for electrostatic interactions with the negative charge 
DNA backbone; and a hydrophobic core (residues 21-39) responsible for protein-protein 
interactions in the major coat. The proximal end of the bacteriophage has five copies of 
minor coat proteins, namely pIII (406 amino acids, and mol wt 42, 522)  and pVI ( 112 
aminoacids, and mol wt 12,342) encoded by Genes III and V1 respectively. pIII is 
essential for virus infection and pVI  is responsible for mediating pIII attachment to virus 
particle. Structurally pIII consists of three separate domains namely two amino terminal 
domains N1 and N2 and one carboxyl terminal CT domain. All these three domains are 
connected by glycine rich repeats. On the other hand, the distal end of phage has 
approximately five copies of two small proteins encoded by Genes VII and IX. They are 
mainly responsible for initiation of viral assembly  [8]. 
 
 
 
 
 
  
   
fi
p
w
 
 
ph
b
in
(p
co
m
pr
 Figure 1-
lamentous b
ermission fr
ith permissi
Figure
age infecti
acterial surf
tegrated wit
ositive stran
mplementa
achinery (p
esence of 
1: Structu
acteriophag
om Ref  [5]
on from Ref
 1-2 shows 
on begins w
ace  [3]. Wh
h bacterial c
d) into the 
ry single st
olymerases
replication 
re of filam
e with rela
. B. Transmi
  [6]. 
the life cyc
ith the bind
en the F- pi
ell membra
host cell cyt
rand (negati
) to form t
proteins pI
3 
entous ba
tive position
ssion electr
le of filamen
ing of N2 
lus on the b
ne and the u
oplasm take
ve strand) D
he double 
I, pX, roll
cteriophag
s of coat p
on microgra
tous bacter
domain of 
acteria is re
ncoating an
s place. Insi
NA is syn
stranded re
ing circle 
e A. Typi
roteins figu
ph of a phag
iophage Ff 
pIII to the 
tracted, the 
d translocat
de the bacte
thesized us
plicative fo
replication 
cal structur
re adapted 
e figure ad
 [9]. Filamen
tip of F-pilu
coat protein
ion of viral 
rial cytopla
ing the hos
rm (RF). In
takes place
e of    
with 
apted 
tous 
s on 
s get 
DNA 
sm, a 
t cell 
 the 
 and 
 pr
h
F
th
pr
co
si
su
F
p
oduces prog
igh concent
inally, durin
e nascent v
ocess, its li
mparatively
mply produ
spension un
igure 1-2: 
ermission fr
eny phage. 
ration, it an
g the extrus
irus  [10]. A
fe cycle is 
 slow cell 
ced in lar
der natural 
Infection c
om Ref  [9])
Later in the
chors and 
ion of proge
s the phage
called non-l
division tha
ge quantiti
and appropr
ycle of fila
. 
4 
 infection, w
sequesters p
ny virus, th
 does not ki
ytic. Howev
n normal ba
es by inoc
iate conditio
mentous b
hen ss-DNA
lus strands
e five coat p
ll the bacter
er, the infe
cterial cells
ulating bac
ns. 
acteriopha
 binding pr
 into filam
roteins are 
ial cells dur
cted bacter
  [11]. Thu
terial cultu
ge Ff (figu
otein pV rea
entous com
incorporated
ing this infe
ial cells und
s, viruses ca
res with p
 
 
 
 
 
 
 
 
re adapted 
ches 
plex. 
 into 
ction 
ergo 
n be 
hage 
with  
5 
 
1.1.2.   Evolution and Construction of Phage libraries  
 
Genetic engineering has been proven to be an invaluable tool in molecular 
biology allowing the direct manipulation of genes in organisms such as bacteria, viruses, 
insect cells, and yeasts resulting in the display of desired guest peptides or proteins on the 
surface of these biomolecules  [12]. Since the inception of genetic engineering in late 
1970’s,  phage based vectors were chosen to be the first cloning vectors  [13]. Later, 
because of their structural simplicity, ability to grow in bacterial hosts, and withstand 
extreme conditions (high pH’s and temperatures) along with greater understanding of 
filamentous phage biology, they were chosen as suitable candidates for phage display.  
Phage display is simply defined as incorporation of foreign peptides/polypeptides 
on the surface of phage particle. This is achieved by splicing a gene encoding a unique 
peptide into the phage genome  [14]. Phage display took its birth in 1985 when  George 
Smith successfully cloned a fragment of EcoR1 endonuclease gene into the middle of  
minor coat protein, pIII of M13 bacteriophage [15]. After that several researchers have 
successfully displayed foreign peptides, proteins and antibodies on the surface of variety 
of viruses. Even though a number of other display systems such as bacteria [16] , 
insects [17] , yeast  [18] and other bacteriophages such as T4  [19] and λ [20] can be 
used, the following discussion is limited to filamentous bacteriophage display.  
 To date most of the filamentous phage display work using genetic engineering 
was limited to M13 and its close relative fd bacteriophage   [21]. Even though any 
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structural protein (either major or minor coat protein) on the virus surface can be used for 
peptide display, fusion of foreign sequence to amino terminus of pIII or pVIII is most 
common approach  [5]. Also, it is believed that minor coat proteins can display larger 
proteins more efficiently than major coat proteins. From previous studies phage can 
withstand up to 38 amino acid residues on the amino terminus of pIII without altering its 
assembly and infectivity  [22]. 
There are several excellent reviews and books which discuss the design, 
construction and applications of phage display libraries [9, 14, 23, 24, 25].  During, 1985 
and 1988 George Smith reported the first construction of random peptide libraries on the 
surface of filamentous bacteriophage and its use in identifying antibody accessible 
peptide inserts   [15, 26, 27]. In 1996, Renata Pasqualini et. al. have reported the first in 
vivo selection of random peptide libraries by studying the organ selective targeting in 
mice models  [28] . Currently these phage libraries are being applied on human beings to 
generate cancer targeting ligands.  In 2006, David Krag et. al. have reported the first 
phase I clinical use of phage display libraries in human cancer patients  [29].  
In general, recombinant peptide libraries are constructed by using two different 
methodologies. One is by using a synthetic degenerate oligonucleotide construct and 
another is by adopting random mutagenesis. The first random peptide library generated 
by George Smith contained fUSE5 as a  cloning vector  [15, 26]. The resulting phage 
library consists of multi-billion recombinant phages generated by fusing random peptides 
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to the N- terminus of all five copies on minor coat proteins pIII or on major coat proteins, 
pVIII.  If the random peptides are present on pIII protein, it is termed as type-3 library; 
and if the random peptides are present on pVIII proteins, then it is termed as type- 8 
library. Even though display of foreign sequences on all five copies of minor coat 
proteins, pIII was achieved two decades ago, the display of fusion peptide on all copies of 
major coat proteins was not successful till recent years. In 1996 Valery Petrenko et. al. 
reported the first construction of landscape phage libraries ( termed owing to the global 
functional moieties on the entire virus surface) [30] using f8-1 as a cloning vector. These 
phage libraries are used in the current dissertation work (as shown in Figure 1-3) and are 
obtained from Valery Petrenko upon request. These libraries are constructed by splicing 
degenerate oligonucleotide sequence into gene VIII  of f8-1 phage based vector by shot 
gun approach  [30]. The resulting recombinant phages with fusion peptides on all copies 
of pVIII subunits are called landscape phages and the collection of these phages are 
known as landscape phages. Similar to complimentary determining regions (CDR) on 
antibodies, foreign peptides are displayed in a fixed frame work on bacteriophage. These 
phage libraries exhibit emergent properties that are specific for a variety of targets. 
Hence, these libraries are mainly used to explore novel protein–protein interactions along 
with other interesting applications as discussed below.  
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1.1.3. Applications of Phage Display Technology 
There are numerous applications of phage display technology including studying 
protein-protein interactions  [31], evaluation of small molecule drug candidates  [32], 
selection of peptide mimotopes for vaccine production  [33], gene targeting  [34], tumor 
targeting  [35]  and epitope mapping  [36]. Here, the discussion is limited to identification 
of novel targeting agents using phage libraries for understanding protein-protein 
interaction. 
 
1.1.3.1. In vitro and In vivo screening of novel receptor-ligands complexes: 
In most cases receptor-ligand (protein-protein) interactions occurs through three 
or four conserved residues (for example: RGD sequence binds to integrins). Hence it is 
believed phage libraries would provide a novel means to identify protein-protein 
interactions. A typical diagnostic assay uses antigens to detect the presence of antibodies 
in serum or blood; similarly phage libraries are used as a rich antigen source to identify 
known or unknown receptors present on a target cell. Thus, it is now possible to define 
the region of a protein/peptide recognized by an antibody based on the motifs revealed 
through phage display  [22, 37].   
Over the past two decades phage libraries have been successfully applied on 
numerous targets to determine epitopes to which antibody binds. Several researchers have 
successfully explored the applications of phage selection against purified antibodies  [15],  
receptors  [38] and whole cell  extract  [39]. Two interesting examples validating the use 
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of phage display technology are binding of tripeptide RGD to integrins bearing cell 
surface receptor  [40] , and identification of highly conserved tyrosine residues when 
phage libraries are screened against SH2 domains  [41].  
Previous studies also confirmed that there is a functional link between the phage 
display identified peptides and receptors. For example, Annexin binds to beta 5 integrin 
and cause programmed cell death  [42]. Previously, Cardo-Vila et. al. have carried out 
identification of β-5 integrins binding peptides using phage display libraries. When they 
synthesized the internalization version of the peptide using penetratin, their study clearly 
demonstrated the trigger of cell apoptosis in a caspase dependent manner  [42]. This 
study validated that both structurally and functionally related targeting ligands can be 
obtained using random peptide libraries.  
Initial studies of phage screening were limited to purified antibodies and 
receptors. Since mid 1990’s to date, phage selection studies tremendously progressed 
towards heterogeneous cell surfaces including complex mammalian cell surface, in vivo 
animal and human tissues. For example, Goodson et.al. have isolated peptide ligands that 
bind to urokinase receptor using phage libraries [43] . Pasqualini et.al. was the first to 
identify targeting ligands that bind to renal and cerebral vacular endothelium using phage 
libraries  [28]. In vivo phage display selection yielded novel targeting ligands against 
benign  [44] and malignant diseases  [45]. Hence, previous studies confirm phage 
libraries have been an in exhaustible tool for recognizing short ligands that specifically 
interact with target macromolecules with distinct confirmations. 
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The resulting cell specific affinity reagents from screening of phage libraries can be used 
for various bio-medical applications including delivery, diagnostics and therapeutics. 
1.2. Cancer 
Despite the progress in science during recent years, cancer continues to be one of the 
leading killers in United States with more than 1 million new cases every year  [46]. 
Current treatment methods not only affect the disease cells but also harm the healthy 
cells. This resulted in a continuous demand for new therapeutic approaches to passively 
or actively destroy the cancer cells. Recent advancement in virology and material science 
provides a new direction to treat tumor. 
 
1.2.1. Breast cancer:  
Breast cancer is a major disease causing death among women in the United States. 
The estimated number of new breast cancer cases among American women  in 2010 is 
approximately 207,090 and  estimated deaths is 39,840  according to the statistics 
provided by American Cancer Society (ACS) in its annual cancer facts and figures  [47].  
Breast cancer is commonly associated with the over expression of epidermal growth 
factor receptors which are responsible for the normal breast tissue development and 
regulation  [48]. Breast cancer is a heterogeneous disease that develops along a 
continuum [49] . There are five stages in breast cancer. Stage 0: It is also known as the 
noninvasive or in situ breast cancer. In this case the cancer cells do not possess an ability 
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to spread to other parts of the body. Stage 1-4 is invasive tumors which mean cancer 
acquires the ability to spread to other parts of the body. Stage 1 is local and can be easily 
cured. Stage 4 is very dangerous and can spread beyond breast to other organs. The 
normal breast terminal ductal lobular unit (TDLU) contains lobules and ducts made up of 
bilayered epithelial cells, namely outer luminal epithelial cell and inner myoepithelial 
cell. Any kind of abnormal changes in the luminal epithelial cells leads to breast cancer. 
During the progression of breast cancer first, atypical ductal hyperplasia (ADH) is 
developed which is characterized by an abnormal cell layers within the duct or lobule. It 
is also thought to be the precursor for ductal carcinoma in situ (DCIS) which gives rise to 
invasive breast cancer. The risk of metastasis increases once the cells start invading. It is 
also shown that the lymph nodes are the primary sites for breast cancer metastasis.  
There are several methods to treat breast cancer patients; treatment usually depends 
on the type and stage of breast cancer. Treatments include surgery followed by additional 
therapy such as radiation, chemotherapy, hormone therapy and immunotherapy to remove 
the tumor tissue completely. However each approach has its own applications and 
limitations. Because of the heterogeneous nature of the breast tissue, it is highly essential 
to develop novel methods that target known or unknown receptors on breast cancer cell 
surface that may find clinical significance in the treatment of human breast cancer.   
1.2.2. ErbB receptors and Signal transduction:  
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All these four receptors share significant difference in their extra cellular and c-
terminal tails but show homology in the kinase domain. Each receptor is characterized by 
binding to a unique ligand leading to protein-protein interactions and diverse signaling 
pathway.  Normal signaling in ErbB receptors involves ligand-induced homo-
dimerization or hetero-dimerization. So far at least twelve different soluble ligands 
binding to ErbB family members were found, including epidermal growth factor (EGF), 
epiregulin, β-cellulin, heparin binding (HB)- EGF, amphiregulin transforming growth 
factor and neuregulins  [48]. Interestingly, to date no soluble ligands that binds to ErbB2 
alone is identified. In addition, it was previously observed that the kinase domain of 
ErbB3 is catalytically inactive. Thus, even though a ligand can efficiently bind to ErbB3, 
it requires a heterodimer partner for signal transduction. When ligand binds (growth 
factor) to a receptor, a conformational change takes place in the extra cellular domain and 
results in the activation of cytoplasmic tyrosine kinase residues and stimulate signaling 
pathways that direct cellular process.   
The activated ErbB receptors can result in diverse signaling pathways (as shown 
in Figure 1-5)  [48]. There are four major signaling pathways used in erbB family 
members: Ras-Raf /MAP-Kinase pathway, STATs pathway, PI3K/Akt pathway and 
PLCγ (Phospho lipase Cγ) pathway. Under regular growth conditions, the expression and 
signal transduction of all these receptors are usually normal. But under extreme 
conditions, such as mutations or alteration in the gene or over expression or activation of 
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1.2.3. ErbB receptor as target for breast cancer treatment :  
As ErbB receptors are over expressed in breast cancer patients, it serves as an 
excellent candidate for targeted anti-cancer therapies  [54].  At present most of the 
targeted approaches to treat breast cancer patients are centered towards ErbB2 receptor 
and other ErbB members.  
There are three different approaches to inhibit the over expression of these 
receptors. One is to inhibit the ligand binding, two is to block the dimerization partner of 
the receptor by using monoclonal antibodies (as shown in Figure 1-6) and three is to 
inhibit the enzyme activity at the cytoplamic end. Currently, several 
biotech/pharmaceutical companies have come up with drugs that selectively inhibit one 
of the above mentioned processes  [55]. Trastuzumab (Herceptin) and cetuximab are 
used in the treatment of breast tumor and colorectal centers by targeting the ErbB2 and 
ErbB1 respectively [56]. Erlotinib (AstraZeneca) and Gefitinib (Genentech/ OSI) are 
two small tyrosine kinase drugs that block the nucleotide binding pocket of ErbB1. 
Tyrosine Kinase inhibitors mainly attack the active tyrosine kinase domain of ErbB 
members and compete with ATP binding. On the other hand, monoclonal antibodies are 
designed to inhibit dimerization and/or induce anti-tumor immune response. Even 
though antibody therapy is an excellent approach to treat breast cancer, because of the 
complexity of cancer biology and the heterogeneous nature of human tissue, a single 
approach is not sufficient to destroy all tumors.  
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  Currently surgery, chemotherapy and radiation therapy represents the most 
common route to treat cancers  [57]. However chemotherapy limitations in non specific 
uptake and inadequate distribution of antitumor agents and drugs resulted in searches for 
new and efficient methods to replace the traditional approaches. As the functional 
elements of biology (DNA, RNA and proteins) are in nanoscale range, nanotechnology is 
setting high expectations to explore biological processes  [58]. Nanotechnology deals 
with the control of matter at the nano level. It utilizes multidisciplinary approach to 
provide devices that are in 1-1000 nm dimension range  [59, 60]. A decade ago 
nanotechnology is primarily focused on attaining monodisperse synthesis and in 
understanding the physical and chemical properties of nanoparticles. Now it is largely 
extended to templated assembly and their biomedical applications. 
 Nanovectors (nano size particles which carry anti tumor drug or imaging agent) 
exhibits unique electronic, optical, magnetic and structural properties. Because of the 
availability of large surface area and easy functionalization with biomolecules, 
nanoparticles are viewed as an attractive agent for targeted cancer treatment  [60]. Even 
though several nanovectors are available for biomedical applications, currently only few 
of them are clinically approved for targeted cancer treatment. Since there are several 
reviews which provide a clear perspective on the use of nanotechnology in cancer 
treatment  [58, 60, 61], here I limit my discussion to few clinically approved nanovectors 
such as liposomes, polymeric nanoparticles  [62, 63, 64] and nanoshells  [65, 66, 67] for 
targeted cancer treatment and their mechanism of action (as shown in Figure 1-7).  
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69]. As the toxicity of the chemotherapeutic drug is enhanced if delivered selectively to a 
target tissue, new approaches for anticancer therapeutics using targeting ligands are 
accelerated  [70]. These ligand mediated therapeutics are designed by associating the 
drug with antigen molecules that specifically binds to the receptors that are over 
expressed or uniquely present on the target cancer cell and not present in normal healthy 
cells. This targeting approach has been successfully applied to nanocarriers such as 
liposome (lipid based), polymers (organic polymer based) and nanoshells (inorganic gold 
based) and resulted in a new source for clinical products.  
In mid-1980’s liposomes emerged as an ideal candidate for drug delivery using 
passive targeting and received special attention because of their unique ability to isolate 
drug from the surrounding environment  [71, 72]. However, the initial liposome 
composites are limited by their circulation times and serum instability. This resulted in 
the modification of liposomes with Polyethylene glycol (PEG) which later increased its in 
vivo circulation time and stability. Currently, conjugation of antigen specific ligands onto 
liposomal fractions carrying anticancer drug greatly improved the therapeutic efficiencies 
and reduced the adverse side effects of chemotherapy  [73]. This resulting complex is 
termed immuno liposomes (as shown in Figure 6). At present, some of these liposome 
encapsulated formulations are in clinical use for Kaposi’s sarcoma, Ovarian and Breast 
cancers  [58]. In addition there are several other drug entrapped liposomal products which 
are in different phases of clinical trial and reviewed in great details elsewhere  [74] .  
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 Polymer-drug conjugates represent another interesting class of nanocarrier in 
which polymers are chemically conjugated with drugs. These polymeric drug conjugates 
contain a water-soluble polymer as a bioactive component to which drug are covalently 
attached. Previous studies showed polymeric micelle formulation of paclitaxel allowed 
increased uptake of the drug at the target site without significant toxicity  [75]. Some of 
the polymer therapeutics such as Zinostatin  and Adagen are currently in market and few 
others are under clinical trials for targeting blood vessels in tumors  [58]. Likewise, metal 
based inorganic nanoparticles For Example:  gold nanoshells (100-200nm size) are being 
used as an excellent source for hyperthermia. The gold nanoshells have central silica as a 
core surrounded by thin layer of gold. Recently, nanoshell based therapeutics received 
great attention in photo thermal therapy  [67] and more recently reached clinical phases 
because of its great success in both in vitro and in vivo systems  [66]. Currently these 
gold based nanoshells are under clinical trials for treating head and neck cancer. 
Nanocarriers reach their target site using two different mechanisms. The first 
being passive targeting, and the second is active targeting.  Passive targeting exploits the 
characteristics of tumor vasculature (leaky blood vessels).  The new blood vessels formed 
in tumor tissue greatly differs from the normal blood vessels due to the presence of 
irregular shape, dilated vessels, and large gaps between endothelial cells. These 
characteristic features in tumor tissue allow the nanocarrier to enter into tumor tissue 
through enhanced permeability and retention effect (EPR effect)  [76, 77, 78]. However 
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passive targeting may not be feasible in all cases as it is a random approach and some 
drugs (>200nm) cannot be diffused efficiently  [58, 79]. In order to overcome the 
limitations resulting from passive targeting, the nanocarrier can be conjugated with 
tumour specific targeting ligands that bind specifically and tightly to cell surface through 
receptor-ligand interactions. The binding of some targeting ligands to the receptor may 
cause receptor-mediated endocytosis  [70, 80] and results in the release of therapeutic 
drugs (as shown in Figure 1-7). For example, Earlier reports showed that certain breast 
cancer cells over express ErbB2 receptors on their surface and when doxorubicin 
encapsulated liposomes targeted with anti-ErbB2 antibody, it improved the therapeutic 
efficiency  relative to the non targeted liposomal fraction  [81]. Thus, the ultimate goal of 
nanotechnology is to properly integrate with established cancer biology (over expressing 
antigens) and develop more versatile, effective, sensitive and safer tools for tumour 
destruction.  
 
1.4. Synthesis, Properties and Biomedical applications of Gold nanorods  
 
1.4.1. Synthesis of Gold nanorods  
Synthesis of metal nanoparticles has been of particular interest to scientists since 
1857 when Michael Faraday was first fascinated by the ruby color of glass and reported 
the first synthesis of colloidal gold  [82]. As the properties of nanoscale materials depend 
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on the size and shape of these particles, it is a great challenge to control the morphology 
of nanoparticles. Fortunately, there has been a tremendous progress in the synthesis of 
gold nanorods in the recent years  [83]. 
 In general, rod shaped nanoparticles can be synthesized in presence of rigid 
template or soft surfactant. Three different approaches are used to synthesize gold 
nanorods: photo chemical reduction method  [84], electrochemical method  [85], and seed 
mediated growth  [86]. In all the methods discussed below, self assembled soft lipids are 
used as a source for the preparation of anisotropic gold nanorods. Among the three 
methods, photochemical reduction is the oldest method used to synthesize colloidal gold 
nanorods  [87]. In this method, gold chloride (HAuCl4) is first interacted with a cationic 
surfactant to form a complex (AuCl4-). When excited with UV light (253 nm), the metal 
ions are reduced to metal through electron transfer mechanism from ions to ligands. 
However, the resulting nanorods had several spherical gold nanoparticles in them. In 
order to synthesize gold nanorods with high yield, quality and mono-dispersity other 
methods are proposed  [83, 85, 88] .  In the electro chemical method, a gold metal plate is 
used as anode and a platinum plate is used as a cathode and are immersed in an electro 
chemical cell with surfactant hexadecyl trimethyl ammonium bromide (CTAB) as an 
electrolytic solution and stabilizing agent  [85].  During electrolysis under controlled 
conditions (temperature and current), the bulk gold metal is converted to gold 
nanoparticles at the interface of cathode surface and electrolyte solution. The addition of 
acetone facilitated cylindrical growth of nanorods with an unknown mechanism  [89].  
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Currently the most common and widely used method to synthesize nanorods is the 
modification of seed mediated growth [83] which was first reported by Jana et.al. in 
2001 [86]. Synthesis of gold nanorods through a seed mediated growth takes place in a 
multi step process. In the first step a seed solution is prepared (3-4 nm of gold 
nanoparticles) by the reduction of gold chloride in the presence of CTAB with a strong 
reducing agent (sodium borohydride). In the second step, the growth of spherical seed is 
converted into rod in the surfactant environment. In the growth phase, mild reducing 
agent such as ascorbic acid is used for the reduction of gold salt into metallic nanorod 
along with the presence of gold seed. The synthesized nanorods are described by aspect 
ratio which is defined as the ratio of longitudinal length to the transverse length. The 
different aspect ratios of gold nanorods are controlled by adjusting the silver ion 
concentration. Thus, using any of the above mentioned methods, the synthesis of one 
dimensional gold nanorod takes place in a two step mechanism. One is crystal 
aggregation or nuclei formation, and the second is crystal stabilization and nanorod 
formation.  
1.4.2. Properties of Gold nanorods  
The properties of materials can be described by the evolution of electronic states 
from atoms to clusters and finally to bulk solids. In most cases, the physical and chemical 
properties of matter depend on the motion of electrons which are largely dependent on 
the type of materials and available space for their motion [89]. In bulk solids the energy 
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Currently, photo thermal therapy using near infra radiations (NIR) is receiving 
tremendous attention. This dissertation is aimed at synthesizing gold nanorods with 
strong absorption properties in the near infra red region (808nm).  
1.4.3. Biomedical applications of Gold nanorods  
Owing to its excellent radiative and non radiative properties and easy conjugation 
with biomolecules,  gold nanorods are emerged as promising tools for biomedical 
applications including sensing, imaging, destruction, drug and gene delivery, and for 
catalytic efficiencies  [89]. The SPR band resulting from absorption or scattering of 
incoming light can be used to monitor the changes in the local environment hence gold 
nanorods are well suited for plasmon sensing.  
Previous studies by Yu et. al. have demonstrated that antibodies conjugated to 
gold nanorods using 11-Mercaptoundecanoic acid (MUDA) as a linker can 
simultaneously be used to detect multiplex surface markers on human breast epithelial 
cancer lines (HBEC)  [97]. Nanorods act as strong contrast agents because of unique 
light-gold nanoparticle interactions (excitation). This enhances linear and nonlinear 
optical properties and offer ability for light scattered imaging  [98]. Previously, Ding et 
al. have used dark field light scattering to image and monitor the uptake of nanorods into 
HeLa cells  [99].  These nanorods can also be used for gene delivery applications. When 
gold nanorods are irradiated with pulse laser, they undergo changes in the shape; hence 
this strategy can be used to deliver DNA into the desired cell. Previous studies by Chen 
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et. al. have successfully demonstrated the release of thiolated enhanced green 
fluorescence protein (EGFP) from EGFP conjugated to gold nanorods using Nd:YLF 
laser  [100]. Their study shows the release is due to thermal and electron heating of the 
particles. Similarly, conjugating gold nanorods with pH/temperature sensitive polymer 
could lead to the release of drug upon laser irradiation. Gold nanorods are also proved to 
be an excellent source of photo thermal agents for cancer destruction. For the first time in 
2006, EI-Sayed and coworkers used plasmonic gold nanorods as photo thermal 
therapeutic agents to selectively destroy human oral cancer cells  [98]. Recent studies are 
focused on their biocompatibility and there in vivo distributions.  Niidome et. al. have 
developed a technique to quantitatively monitor the accumulation of gold nanorods  in 
vivo animal models  [101].  
Thus gold nanorods provide exceptional optical properties for wide range of 
applications including cancer diagnosis and treatment. From recent progress in science 
using gold nanorods as photo thermal agents, there is a great chance for its advancement 
into clinical trials in the near future. The current research is also focused on 
understanding their role at molecular level. 
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1.5 Aims and Scope of this Dissertation.  
A transition has occurred over the period of time in replacing the concept of virus 
as a toxic pathogenic agent to a useful agent for biomedical applications. In the last two 
decades, phage display technology is emerged as a powerful tool to identify unique 
cancer targeting ligands which can serve as a substituent’s to antibodies. More recently, 
nanovectors with unique physical and chemical properties are currently being evolved as 
alternative tools for cancer diagnosis and treatment. Therefore, integration of engineered 
phage or phage derived components with nanomaterials might result in attractive and in- 
expensive tools for cancer imaging and therapy. Thus, the primary goal of this 
dissertation is to identify novel targeting ligands on SKBR-3 breast cancer cell surface 
and synthesize novel protein/peptide nanoconjugates that can be used for imaging and 
destruction of these breast cancer cells. In order to achieve this goal, the aims are 1) To 
identify and characterize new SKBR-3 breast cancer cell targeting ligands using 
landscape phage libraries and understand their mechanism of entry. 2)  Synthesize multi 
functional nanoconjugates for cancer diagnosis and treatment and understand its role at 
molecular level. 3) Genetically modify bacteriophage surface and conjugate with 
nanoparticles for other biomedical applications. 
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Chapter 2 : Identification and Characterization of SKBR-3 breast 
cancer cell specific targeting peptides using landscape phage libraries. 
 
2.1 Introduction   
Breast cancer is one of the most serious deaths causing disease among women. 
Identification of new breast cancer cell-specific targeting or internalizing peptides is 
attractive for cancer imaging and therapy because they  serve as excellent substitutes for 
antibodies on nanomaterials which are limited by their large size, cost of production and 
non specific binding to reticuloendothelial system  [102].   
The search for new cell-penetrating peptides has been very active in the recent 
years because they can assist in delivering molecules to a variety of cells. Earlier studies 
on tat protein from HIV-1 and antennapedia homeodomain from drosophila showed that 
short protein domains can cross the plasma membrane through translocation process 
 [103, 104]. These studies indicated that small proteins or short peptides can enter the 
cells. However, cell-penetrating peptides are limited in applications because of their lack 
of specificity to a particular cell  [102]. Such limitation has led the scientists to search for 
new cell targeting/ internalizing peptides that can show specific binding affinity against a 
target cell.  
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These cell-targeting peptides which are specific to a particular cell can be uptaken 
into the cells through initial electrostatic interactions between their amino acids and 
plasma membrane components and internalized by endocytosis or energy independent 
methods  [105]. RGD is one of the most extensively studied cell-targeting peptides  [106] 
and its derivatives, such as galacto-RGD, have already been used in therapeutic assays 
 [106]. Phage particles displaying cyclic peptide RGD4C can bind surface integrins and 
be effectively internalized into cells  [107]. Recently, the heptapeptide LTVSPWY was 
also identified as a potential cell-targeting peptide against the ErbB2 receptor  [108]. 
However, there is a need for more diverse repertoire of the cell-targeting and 
internalizing peptides that can help in diagnosis and treatment of breast cancer.   
ErbB2 (also called HER2) is a very attractive target for cancer cell-specific 
detection and treatment because it’s over expression may result in neoplastic 
transformation  [109].  It is one of the four members of ErbB family receptors as 
described in chapter 1. Human ErbB2 is a large glycoprotein with 1234 amino acid 
residues. Like EGFR, the extracellular portion of human ErbB2 (1-632 residues) consists 
of four domains (I-IV) designated as L1, CR1, L2, and CR2  [110, 111]. ErbB2 acts as a 
major signal transducer following ligand-driven recruitment into heteromeric complex 
with other ErbB family members (such as ErbB1, ErbB3 and ErbB4), but it does not bind 
specifically to any known ligand of ErbB family  [112]. Other members of ErbB family 
such as ErbB1, ErbB3 and ErbB4 can selectively bind to ligands such as epidermal 
growth factor (EGF), transforming growth factor α (TGF α), amphiregulin, β-cellulin, 
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epiregulin, epigen, heparin binding EGF and the neuregulins  [109, 110, 111, 113]. The 
binding of these ligands and dimerization leads to the activation of tyrosine kinase 
domain and results in cellular signaling  [114, 115]. Since human breast carcinoma 
SKBR-3 cells over express the ErbB2 receptor  [109], it is a plausible target for cancer 
cell-targeting ligands. Development of the short peptide ligands that can specifically 
recognize the uniquely expressed proteins on cancer cells could facilitate the design of 
cell-targeting nanomedicines for cancer diagnosis and treatment.  
Phage display has been demonstrated to be a powerful approach for the selection 
of short cell-targeting or internalizing ligands  [116]. The principles and applications of 
phage display for studying protein-ligand interactions were reviewed elsewhere  [23, 
117]. To identify cell-binding peptides, a phage-displayed random peptide library is 
allowed to interact with target cells (in our case SKBR-3 cells), then the unbound phages 
are washed away and the bound phages are eluted by using an elution buffer  [116]. The 
phage that is specifically internalized in the target cells during the selection process can 
be obtained by lysing the cells to release the cell-internalized phage.  
One of the advantages of using phage display to select short cancer cell-targeting 
or internalizing peptides is that no prior information on the landscape of the cancer cells 
is needed before desired peptides are selected. Since the receptors over expressed on the 
cancer cells can be the preferred targeting sites for the phage-displayed peptides, we used 
human breast carcinoma cells SKBR-3 as a model, which are known to over express 
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ErbB2 receptors  [118]. For selection of cell-binding and/or penetrating phages that can 
specifically target the SKBR-3 cells, we used landscape phage library – a multibillion 
collection of phages with random octamers fused to each copy of the major coat protein 
(called pVIII).  The multivalent display of the binding peptides in the landscape phage 
dramatically increases the affinity of peptide-cell interaction because of avidity effect and 
increases a repertoire of selected binding clones  [119].  Furthermore, the fusion pVIII 
protein comprises a dominant fraction (~95%) of viral mass and can be directly converted 
into specifically targeted drug- and gene-delivery vehicles  [120, 121, 122]. The general 
strategy of the selection of cell-targeting/internalizing peptide by using a landscape phage 
library is outlined in Figure 2-1.  
2.2 Experiments Performed 
 
2.2.1. Landscape phage library and cells used  
We used an 8-mer landscape phage display library (called f8/8) in our selection 
experiments. The detailed information about the library construction were described 
elsewhere  [123]. Random peptides in this library are fused to N-terminus of the major 
coat protein pVIII of fd-tet bacteriophage, so that each landscape phage virion displays a 
unique 8-mer random peptide on each of the 3900 copies of pVIII.  The human breast 
carcinoma SKBR-3 (HER-2 positive) cells were obtained from the American Type 
Culture Collection (ATCC, Rockville,MD). As a control we used normal breast MCF-
10A (HER-2 negative) cells purchased from ATCC. 
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 2.2.2. Mammalian cell culture  
The target SKBR-3 cells and control MCF-10A cells obtained from ATCC were 
cultured in 25 cm2 culture flask containing McCoys 5A modified medium and 
Dulbecco’s modified Eagles medium (DMEM)  respectively supplemented with 10% ( 
v/v) fetal bovine serum, 11.2 μg/L penicillin, 11.2 μg/L stepromycin, and 11.2 μg/L 
ampicillin. The cells were incubated at 370C with 5% CO2, and the cell culture medium 
was changed once in two days until the cells reached 90% confluence. The cells were 
harvested by 5 min incubation at 370C with a 0.25% trypsin, 1 mM EDTA solution 
followed by centrifugation at 2100 rpm for 5 min. The cell pellet was dissolved in 5 ml of 
medium and cell count was determined. The Phase contrast images of target SKBR-3 
cells and control MCF-10A cells are shown in Figure 2-2. 
 
2.2.3. Preparation of the bacterial host starved cells  
A fresh loop of E. Coli K91 BlueKan cells was inoculated into three test tubes 
containing 2 ml NZY/Kanamycin (100 μg/ml) in each tube. The tubes were incubated in 
a shaking incubator at 220 rpm at 37oC overnight. 300 μl of overnight cultures were 
transferred into a 250 ml flask containing 20 ml NZY medium. The flask was incubated 
at 220 rpm, 370 C until OD600 =0.45, followed by gently shaking (50 rpm) for additional 
8 min. The cells in the sterile tube were then centrifuged at 2000g for 10 min at 4oC. The 
supernatant was discarded and the cells were gently re-suspended in 20 ml of 80 mM 
NaCl solution. The re-suspended solution was then gently shaken at 50 rpm for 45 min, 
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followed by centrifugation as above. The cell pellet was re-suspended in 1 ml of cold 
sodium ammonium phosphate buffer (NAP buffer) (80 mM NaCl, 50mM NaH4PO4 
pH=7.0 adjusted with NH4OH) and stored in a refrigerator. 
 
2.2.4. Affinity selection of SKBR-3 cell-binding phage clones  
The affinity selection procedure as shown in Figure 2-1 was followed with a 
slight modification of a previously reported protocol described elsewhere  [116]. Briefly, 
the landscape phage library (~1x109 phage virions) was first incubated with empty 25 
cm2 culture flask at 37oC for 1 h to remove the phages that non-specifically bound to the 
culture flask. This process is known as depletion. The resultant depleted library was then 
used as an input library to the culture flask containing the control MCF-10A cells (HER-2 
negative cells). This process is known as negative selection, which was performed to 
remove phage that binds to the receptors of healthy cells and increase a portion of the 
phage binding target SKBR-3 cancer cells. The depleted phage library was transferred to 
the flask with target SKBR-3 cancer cells (HER positive cells), and incubated at 37oC for 
1 h.  The flask was washed 10 times with Bovine Serum Albumin (BSA)/Tween washing 
buffer to remove the unbound phages. The cell surface bound phages were eluted from 
the culture flask with 800 μl of low pH elution buffer (0.1N HCl, 1mg/ml BSA and pH 
adjusted to 2.2 with glycine) for 10 min. The eluate was transferred into a 1.5 ml 
eppendorf tube and neutralized by mixing it with 150 μl of 1 M Tris-HCl (pH= 9.1) 
immediately. At the same time, the cell internalized phages were recovered using a cell 
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lysis buffer (2% sodiumdeoxycholate, 10 mM Tris, 2 mM EDTA, pH 8.0).The tubes were 
stored at 40C for further use. 
 
2.2.5. Amplification of eluates  
The entire first-round eluate (950 μl) was concentrated to reach a final volume of 
150 μl by using a Centricon 100-KDa Ultrafilter (Amicon). 150 μl of concentrated eluate 
was added to 150 μl of the starved cells and incubated for 15 min at room temperature. 
The phage-infected cells were transferred to 40 ml of NZY medium with tetracycline (0.2 
μg/ml) in a 125 ml flask and incubated for 45 min at 37oC with shaking. The tetracycline 
concentration was increased to 20 μg/ml and the shaking of the flask was continued at 
37oC for 16-24 h. 
 
2.2.6. Amplification of cell lysate fraction  
The SKBR-3 cell-internalized phage clones were recovered using the cell lysis 
buffer (2% sodiumdeoxycholate, 10 mM Tris, 2 mM EDTA, pH 8.0). In order to recover 
internalized phages, the cell monolayer from the cell culture flask was scraped with a 
sterile pasture pipette and taken into 5 ml of cell culture medium and centrifuged at 130 g 
for 10 min. Later, the supernatant was removed and 200 μl of the cell lysis buffer was 
added to the pellet. The fraction was stored at 4oC until amplification. The phages were 
used for amplification and further selection as stated above.   
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2.2.7. Purification of amplified phages by using double PEG precipitation  
Phage was purified by double polyethylene glycol (PEG) precipitation as 
described previously  [124]. Briefly, 40 ml of NZY medium containing 20 µg/ml 
tetracycline was inoculated with a fresh single colony of phage-infected cells in a 250 ml 
flask. The culture was incubated in a shaking-incubator at 200 rpm, 37oC overnight. The 
overnight culture was poured into a 250 ml Beckman centrifuge bottle and centrifuged at 
3000 g for 10 min at 4oC. The supernatant was then poured into a fresh tube and 
centrifuged at 9300 rpm for 10 min at 4oC. The resultant cleared supernatant was again 
poured into a fresh tube, to which 6 ml PEG/NaCl solution (100 g PEG 8000, 116.9 g 
NaCl and 475 ml water) was then added. The tube was kept at 40C overnight for phage 
precipitation. The precipitated phages were collected by centrifugation at 13000 rpm for 
60 min and the supernatant was removed. The pellet was then dissolved in 1 ml Tris 
buffered saline (TBS) in a micro-centrifuge tube and centrifuged again at 13000 rpm for 
10 min to remove any undissolved material. 150 μl of the PEG/NaCl solution was added 
to the supernatant which was then kept on ice overnight. The tube was then centrifuged at 
13000 rpm at 4oC for 60 min and the supernatant was removed. The final pellet was 
dissolved in 200 μl TBS and vortexed thoroughly. 
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2.2.8. Titering of phage  
Serial dilutions (10-2 -10-8) were prepared by using TBS (pH 7.4). For example, a 
10-2 dilution was reached by taking 10 µl of phage in 490 µl of TBS and 500 µl of 
sterilized water. In a 1.5 ml eppendorf tube 10 µl of starved cells were mixed with 10 µl 
of each phage dilution and incubated for 15 min at room temperature. 180 µl NZY with 
tetracycline (0.2 μg/ml) was added to each tube and the tube was incubated for 45 min at 
37o C. Suspensions from the tubes were spread onto NZY plates with tetracycline (20 
μg/ml). The plates were incubated overnight at 37o C in an incubator and the number of 
colonies on the plates was counted the following day. The phage titer was calculated as 
follows: 
                  Titer = N X 100 X dilution factor, where N= number of colonies formed 
 
2.2.9. Second- fourth rounds of affinity selection  
The purified phage after each round was used as an input library for the next 
round of selection (Figure 2-1), which proceeded similar to the first round described. 
After the fourth round of selection, the eluted as well as lysate phages were not amplified. 
Instead, they were titered and 65 random colonies were picked up for sequencing in order 
to determine the SKBR-3-binding peptides that were fused to the major coat protein 
pVIII of the selected phages. 
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2.2.10. Sequencing of selected phage colonies  
Each colony of phage infected E. Coli K91 BlueKan cells on the plates was 
inoculated into a tube containing 2 ml NZY/Tetracycline (20 μg/ml) and the tubes were 
kept in the shaking incubator at 220 rpm, 37o C overnight. 1 ml culture from each tube of 
phage infected K91 BlueKan cells and 30 µl of 830 µM related primer (5’ –
CAAAGCCTCCGTAGCCGTTG-3’) were sent to MC Lab Inc. for sequencing. The 
nucleic acid sequences of the insert-coding region of the phage DNA were translated to 
the corresponding peptide sequences using EB1 tool Transeq. 
 
2.2.11. Phage capture ELISA on target SKBR-3 cells 
Phages that specifically interact with the SKBR-3 cells due to the presence of 
specific peptides fused to the major coat protein were revealed using phage capture 
ELISA. The target cells (SKBR-3) and control cells (MCF-10A) (~1 x104 cells/well) 
were applied to a 24 well plate and incubated at 370C overnight. All the wells were 
blocked with 100 μl of 0.1% bovine serum albumin (BSA) and incubated at room 
temperature for 1 h. Later each well was washed five times with 200 μl of TBS 
containing 0.5% Tween 20, and 50 μl (1x1010 virions/ml) of purified phage preparation 
was applied to SKBR-3 cell-coated wells, MCF-10A cell-coated wells and an empty well, 
which were then incubated at room temperature for 1h with gentle mixing. After 
incubation the plates were washed with 200 μl of TBS buffer and supplemented with 40 
μl of anti-fd bacteriophage IgG. The plates were then incubated at room temperature for 1 
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h, washed with TBS buffer and incubated with 40 μl of anti rabbit IgG conjugated with 
alkaline phosphatase at room temperature for 1 h. After a final washing step, alkaline 
phosphatase substrate, p-nitrophenyl phosphate, was added to the wells and the 
absorbance was measured at 405 nm using a plate reader. The p-nitrophenyl phosphate is 
a substrate, which turns yellow when cleaved by alkaline phosphatase. A relative amount 
of phage bound to the cells was determined by measuring the rate of color change in each 
well.  
 
2.2.12. Immunofluorescence studies of phage-cell interactions  
The SKBR-3 cells were cultured on a cover slip in a six well plate. Two days after 
seeding, the medium was removed and the cells were incubated in serum-free medium for 
1 h. Later, the serum free medium was removed and approximately 1x109 phages in TBS 
were added to the chamber and incubated at 370 C for 1 h. The cells were washed three 
times with PBS and fixed in 4% formaldehyde in PBS for 15 min. The fixed cells were 
washed three times in PBS and incubated for 1 h in room temperature with 1:10 dilution 
of Alexa Fluor conjugated anti–pIII antibody. The detailed procedure for conjugation of 
dye and antibody and purification of dye-conjugated antiboby from free dye can be 
obtained from Invitrogen Alexa Fluor® 488 Monoclonal antibody labeling Kits (cat# A-
20181). The cover slips were washed 5 times with PBS and then incubated with DAPI, a 
nuclear staining dye, for 5 min. The cover slips were again washed for 5 more times with 
PBS and mounted on a microscope slide. The cells were examined using a Zeiss 
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Universal epiflourescence microscope equipped with Olympus oil immersion DApo UV 
objectives. Digital images of cells were collected using Olympus DP-70 camera and 
software. 
 
2.2.13. Energy dependent mechanism of phage entry 
 In order to determine the energy-dependency of phage entry, SKBR-3 cells were 
incubated with phage clone, labeled with rhodamine B at either 37oC (in presence and 
absence of inhibitors) or 4oC. Briefly,  rhodamine B labeling of engineered phages was 
performed by mixing 0.2 g of a coupling agent, 1-[3-(Dimethylamino)propyl]-3-
ethylcarbodiimide hydrochloride (EDC), and 2.5 mg of rhodamine B in 10 mL of affinity 
selected phage stock solution (1x1012 pfu) in phosphate buffer (pH 5.6). This procedure 
results in the attachment of the dye through EDC assisted caging. The rhodamine-labeled 
phages were extensively dialyzed for 3 days under stirring to remove unbound dye 
molecules. The modified phages were stored at 4oC in dark until further use. SKBR-3 
cells were seeded 48 h prior to phage incubation on cover glasses in the six-well plates 
(8000 cells/well). The growth medium was replaced with 200 µl of rhodamine conjugated 
phage in PBS (1x109 cfu/ml), and cells were incubated for 1 h, either at 37oC (in the 
absence and presence of ATP inhibitors) or at 4oC (all the solutions were prechilled to 
4oC). Later the cells were extensively washed three times with PBS at corresponding 
temperature and fixed in 4% paraformaldehyde in PBS for 15 min at 37oC. After 
incubation the cells were washed twice with PBS and stained with 250 µl of DAPI (1 
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µg/ml) for 5 min, the cover slips were again washed for 5 more times with PBS and 
mounted on a microscope slide. The cells were examined under Zeiss Universal 
epiflourescence microscope equipped with Olympus oil immersion DApo UV objectives. 
Digital images of cells were collected using Olympus DP-70 camera and software. 
 
2.2.14. Quantification of cell associated phage on target and control cell lines  
The specificity was determined by comparing the selected phage binding to a 
control wild type phage (f8-5 vector without any foreign insert) on target SKBR-3 cells. 
To test the selectivity, L1 phage was incubated with target SKBR-3 cells and other 
control cell lines. Controls used in this study are MCF-10A cells obtained from ATCC, 
Fibroblasts, Mesenchymal stem cells (MSCs), and Squamous cell carcinoma (SCC-15) 
(sourced from Cell Culture Core facility at BWH Dermatology/Harvard Skin Disease 
Research Center, Harvard Institutes of Medicine, and USA). All the cells are cultured at 
37°C in a humidified sterile atmosphere of 95% air and 5% CO2, using recommended 
procedures. Once the cells reached 90% confluence, the target and control cells were 
incubated with 1x 109 pfu/ml of L1 phage in blocking buffer for 1h at 370C. Before, the 
additions of phage, the cells are first incubated with serum free medium for 1h at 370C. 
The phage bound to the target and control cells were isolated using elution and lysis 
buffer as stated before. The phage titers were obtained by bacterial infection of recovered 
phage and represented as output to input phage. All experiments were done in triplicates. 
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2.2.15. Blocking of L1 phage uptake by 12 mer synthetic peptide  
Target SKBR-3 cells were cultured in 25cm2 tissue culture flask and incubated 
with 2 ml of  VSSTQDFPDPAK synthetic peptide (Neopeptide, Cambridge, 
Massachusetts) in Mc Coy’s 5A medium at concentration 0.25mM, 0.75mM and 
1.25mM. These concentrations of synthetic peptide were incubated with the SKBR-3 
cells for 1hr at 40C as previously described.  [125] After incubation, 1x109 cfu of L1 
phage in 1ml of blocking buffer was added to the cells and incubated for 1 h at 370C. 
Unbound phage was removed using sterile pasteur pipette and the cells were thoroughly 
washed five times for 5 min each with cold washing buffer. The phage associated with 
cells in presence of synthetic peptide was recovered with lysis buffer as described above. 
The amount of phage bound was quantified using titration method. 
 
2.2.16 Live cell imaging of landscape phage treated SKBR-3 cells using video 
microscopy  
SKBR-3 cells cultured on 25-mm cover glasses were transferred to a perfusion 
filming chamber. The chamber was placed on Zeiss Standard microscope stage 
maintained at 37°C with an air curtain incubator. The cell images were recorded with 
Hamamatsu C2400 camera and Scion software. Cells were recorded for 15 min in 
McCoy’s 5a medium and then 1x109 cfu/ ml selected phage was perfused into the 
chamber from a 2.5-cc syringe driven by a syringe pump (Sage model 341 A) and 
recorded for additional 45 min. 
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2.2.17 Immunofluorescence of labeled F-actin with phage internalization  
The SKBR-3 cells were cultured on the cover glasses in a six well plate. Two 
days after seeding, the medium was removed and the cells were incubated in serum-free 
medium for 2 h. The medium was removed and 200 μL of phage suspension 
(approximately 1x109 virions/ml in TBS) in cell culture medium was added to each well 
and incubated at 370 C for 15 min, 30 min, and 45 min respectively. The cells were 
washed three times with D-PBS and fixed in 4% paraformaldehyde in D-PBS for 15 min. 
The fixed cells were washed three times in D-PBS and incubated with 2 µM rhodamine-
phalloidin in D-PBS for 15 min in dark at room temperature. The cover glasses were 
washed 5 times with D-PBS and mounted on a microscope slide. The cells were 
examined using an Olympus fluoview FV 500 confocal laser scanning microscope and 
the images were acquired at constant PMT, gain, offset, magnification (60 x objectives) 
and resolution.  
 
2.2.18 Statistical analysis  
All the statistical analyses were performed using student unpaired two-sided t-test 
analysis as stated before  [126]. P values were considered to be statistically significant 
with p< 0.0002.  
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2.2.19 Preparation of Cross-Linked L1 Phage  
L1 phage was cross-linked to dextran polymer as reported by Smith et.al.  [127] 
and Samaoylova et. al.  [128]. In this procedure 1 ml of L1 phage (1.6 × 1013 virions/mL) 
in coupling buffer was mixed with 10 μL of N-hydroxysuccinimide-dextran (NHS-
dextran; a water-soluble multifunctional dextran polymer custom-synthesized by 
CarboMer, Westborough, MA, USA) in a 1.5 ml eppendorf tube. The mixture was 
vortexed and 150 μL of 50% PEG in water is added immediately. The reaction mixture 
was incubated under shaking for overnight at room temperature. The following day, the 
solution was transferred to 15ml centrifuge tube and the unreacted N-hydroxysuccinimide 
(NHS) groups were quenched by the addition of 8 mL of 1 M Tris-HCl, pH  9.5, and 890 
μL 5 M NaCl. The resulting mixture is kept under shaking for an additional 1–2 h at 
room temperature. The cross-linked phage was pelleted by centrifugation (12,000× g) for 
15 min, washed thoroughly and the final pellet of cross-linked phage is suspended in 1ml 
of TBS. The concentration of the cross-linked phage was determined 
spectrophotometrically and solution is stored at 4oC until further use. 
 
2.2.20 Isolation and analysis of SKBR-3 cell lysate using Cross-Linked L1 Phage  
SKBR-3 cells were cultured in six 25 cm2 flasks till they reached 90% confluence. The 
medium was removed, and the cells were rinsed with ice-cold PBS buffer. The cells were 
lysed in cell lysis buffer (purchased from Sigma) with protease inhibitor cocktail (Sigma) for 
15 min at 37°C. In one flask, intact SKBR-3 cells were biotinylated with the EZ-Link Sulfo-
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NHS-LC-LC Biotin (Pierce, Rockford, IL, USA) prior to cell lysis. All the lysates were 
centrifuged and the supernatant was used for the isolation of SKBR-3 cell membrane pro-
teins. Later, the lysate fractions were incubated with cross-linked LI phage (1013 virions) 
under shaking for overnight at 4°C. Finally, the cross-linked phage with cell components 
was pelleted at 20,000× g for 15 min at 4°C. At the end cell components bound to the 
phage was eluted with 200 μL of elution buffer (0.1% BSA, 0.2 M glycine-HCl, pH 2.2) 
for 15 min at 4°C. The phage matrix was separated from eluate by centrifugation for 10 
min at 13000 rpm. The eluate was transferred to a fresh microcentrifuge tube and 
neutralized with 37.5 μL of 1 M Tris-HCl, pH 9.0. Finally, the cell lysate, clarified cell 
lysate, biotinylated SKBR-3 cell lysate,  and proteins isolated through L1 phage matrix 
fractions were separated by 12% sodium dodecyl sulfate- polyacrylamide gel 
electrophoresis (SDS-PAGE) and protein isolated was further analyzed using N-terminal 
protein sequencing and mass spectrophometer analysis.  
 
2.3 Results 
 
2.3.1 Selection of cell targeting/internalizing phage against SKBR-3 cells  
Phage clones that bound to SKBR-3 cells were selected from the landscape phage 
library f8/8  [123] through successive rounds of affinity selection procedure, in which the 
phage library was incubated with SKBR-3 cells cultured in a 25 cm2 tissue culture flask 
(as shown in Figure 2-1). During the affinity selection process, the unbound phages were 
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washed away and the cell surface bound phages were eluted with mild acid treatment. It 
should be noted that phage library was allowed to interact with normal breast cells first in 
order to get rid of phages that might bind to normal cells before interacting with breast 
cancer cells. During each round of affinity selection, after cell-surface-bound phages 
were eluted, the cells were lysed to release the cell-internalized phages to obtain cell-
internalizing peptides. The cell-internalized phages were recovered from cell lysates. 
Phages that bound to SKBR-3 breast cancer cell surface and internalized in the initial 
selection procedure were amplified separately by infecting bacteria and used as the input 
for the next round of affinity selection. This procedure was repeated four times. After the 
fourth round of affinity selection, 65 clones were randomly picked from both the eluate 
and lysate fraction and a segment of genomic DNA encoding the octapeptide (i.e., insert-
coding region) was sequenced. The cell-surface-targeting peptides (denoted as S) and 
cell-internalizing peptides (denoted as L) and their frequencies were shown in Table 2-1a 
and Table 2-1b, respectively. A comparison between them indicates that two peptides 
(DGSIPWST and VSSTQDFP) are both surface-targeting and cell-internalizing. 
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Table 2-1a: New SKBR-3 cell targeting peptide clones recovered from landscape 
phage library by using an elution buffer.  S: denotes cell surface binding fraction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell-Targeting clones 
Clone ID Motif  sequence Frequency 
S1 DGSIPWST 13 
S2 VSSTQDFP 10 
S3 DNGSGISW 5 
S4 DTKTAPAW 3 
S5 GSTDSDLK 2 
S6 ATTAPSYP 1 
S7 AAATKSDL 1 
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Table 2-1b: New SKBR-3 cell internalizing peptide clones recovered from landscape 
phage library by using a lysis buffer.  L: denotes cell internalizing fraction. Table 
obtained with permission from Ref  [39]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2 Characterization of selected peptides and phages:  
Selected peptides were analyzed using the REceptor Ligand Contacts (RELIC) 
program,  which is a bioinformatics tool for combinatorial peptide analysis and 
identification of protein-ligand interaction sites  [131]. A complete review of RELIC and 
New Cell-internalizing clones 
Clone ID Motif  sequence Frequency 
L1 VSSTQDFP 13 
L2 DGSIPWST 8 
L3 AFSEAAQT 5 
L4 ADAPSNGW 1 
L5 DNDNYAFP 1 
L6 DYADYSDL 1 
L7 AADYDPLA 1 
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its principle and application in analyzing affinity selected peptides can be found in the 
literature  [131]. We used two RELIC programs (RELIC/POPDIV and RELIC/INFO) to 
analyze the binding affinity of our selected peptides towards SKBR-3 cancer cells.  
RELIC/POPDIV program uses a statistical sampling method to estimate the sequence 
diversity of a combinatorial peptide library based on the sequence obtained from a 
limited number of randomly sampled members of the library. According to this program, 
affinity selected peptides towards target SKBR-3 cells should have a less diversity than 
an equivalent number of randomly selected peptides from the native library. It has been 
demonstrated that the decrease in the diversity of the sequences obtained from successive 
rounds of selection is an indicator of affinity selection  [132, 133, 134].  
We calculated the diversities of both affinity selected peptides and random 
peptides from the native library by using RELIC/POPDIV program. Our affinity selected 
peptides yielded a diversity value of 0.00402 whereas the same number of randomly 
selected peptides from a native library yielded a diversity value of 0.00913. Compared to 
randomly selected peptides, our affinity selected peptides have a less diversified 
population, which is a clear evidence for successful selection of peptides with binding 
affinity towards SKBR-3 cells.  
In order to verify that the selected peptides were from affinity selection and not 
from amplification noise, we used RELIC/INFO program because the noise from 
amplification has regular and measurable patterns  [133, 134]. This program was 
designed to initially calculate the noise pattern and then subtract the noise pattern from 
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the affinity pattern to obtain information content  [131]. Information content is defined as 
–ln(PN), where PN is the probability of randomly finding a given peptide. The principle of 
RELIC/INFO helps in determining the occurrence of information content of the affinity 
selected peptides and thereby confirms the binding affinity of selected peptides after 
affinity selection. A larger information content (-lnPN) of a peptide indicates a greater 
chance of observing this peptide in affinity selection due to specific binding to the target. 
Indeed, from Figure 2-3 the normalized distribution of the information content for our 
SKBR-3 selected peptides is positively shifted towards higher information content in 
comparison to that of the peptides selected from native phage library. This positive shift 
of red curve in Figure 2-3 suggests that our SKBR-3-selected peptides results from 
affinity selection. Both observed result are in accordance with the principle of 
RELIC/POPDIV and RELIC/INFO  [131].  
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antibody conjugated to Alexa Flour (No fluorescence indicates WT phage is not binding). 
(C, D) Cells treated with identified cell-internalizing phage (displaying peptide L1) and 
stained with DAPI and anti-phage antibody-labeled Alexa fluor fluorescently, showing 
the corresponding blue fluorescence from nuclei and green fluorescence resulting from 
the internalization of phage. (E, F)  Cells treated with identified cell-internalizing phage 
in presence and stained with DAPI and anti-phage antibody-Alexa fluor.  
 
To see the motif similarities between peptide inserts from selected phages and 
natural ligands binding to ErbB family receptors, we used RELIC/MATCH program to 
align our selected peptide sequences with the sequences of the proteins that were reported 
to recognize SKBR-3 cells. The alignment results are shown in Table 2-2 and 2-3 and 
suggest that our selected peptides show similarity with some domains on the proteins, 
which are known to recognize SKBR3 cells, including antibodies. 
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2.3.3 Mechanism of phage entry into target SKBR-3 cells.  
In order to understand the mechanism of phage entry into SKBR-3 cells, initial 
experiments were conducted to determine the energy dependency of L1 phage uptake 
because endocytosis can be strongly inhibited by lowering the temperature  [135]. For 
this purpose, selected phages were labeled with rhodamine as described earlier  [136]. 
Phages conjugated to rhodamine were then incubated with SKBR-3 cells at 37oC (in the 
absence of ATP inhibitors), at 4oC and at 37oC (in the presence of ATP inhibitors, 
sucrose and sodium azide). As shown in Figure 2-6, the phage uptake is only active at 
37oC in the absence of inhibitors. In contrast, lowering the temperature completely or in 
the presence of inhibitors reduced the phage uptake as shown in Figure 2-6 (D-I). The 
phage internalization efficiency was found to be less than 5% at 4oC and in the presence 
of inhibitors as compared to phage internalization efficiency at 37oC. These findings 
confirm that selected L1 phage enters the SKBR-3 cells by energy-dependent uptake 
mechanism.  
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azide). [A,D,G-rhodamine specific filter; B,E,H- rhodamine and DAPI specific filters; 
C,F,I- DAPI specific filter. Figure obtained with permission from Ref  [129] 
 
2.3.4 Competitive binding studies using synthetic peptide.  
SKBR-3 cell internalizing phage clone, L1 bears VSSTQDFP peptide sequence 
on its N-terminus. In order to test whether L1 phage internalization takes place through a 
VSSTQDFP recognition motif, we performed competitive assay using a synthetic 
VSSTQDFPDPAK peptide. As described in earlier section, synthetic peptide was 
incubated with the cells prior to the incubation of L1 phage. Figure 2-7 shows that 
incubation of synthetic peptide reduced the L1 phage binding to the SKBR-3 cells in a 
concentration dependent manner. As the concentration of peptide is increased less 
number of L1 phage was bound to the cells. This confirms that L1 phage internalization 
is competitively inhibited in presence of synthetic peptide. 
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2.3.5 Actin dynamics during the phage internalization into SKBR-3 cells:  
In order to understand the mechanism of selected phage internalization into 
SKBR-3 cells, we first performed video microscopy to observe the behavior of SKBR-3 
cells before and after the treatment of cells with internalizing phage (L1). SKBR-3 cells 
are polygonal cells and display cycles of protrusions and withdrawals of small 
lamellipodia at the cell edges forming small ruffles at random places around their 
periphery. The dorsal (upper) cell surface is relatively quiescent, with occasional small 
ruffles (Figure 2-8 a-c). After injection of internalizing phage into the filming chamber, 
SKBR-3 cells showed very intense ruffling in multiple places around the cell periphery. 
Cells were also rapidly forming numerous ruffles on their dorsal surfaces. As shown in 
Figure 2-8 d-f, cell edges and dorsal surface stay very active over the entire time of 
recording (45 min). In the control, no significant changes were observed in the behavior 
of cells before and after the addition of control wild type phage Figure 2-9 a-f. The 
representative still images of SKBR-3 cells before and after the addition of selected 
phage and WT phage are shown in Figures 2-8 and 2-9. The original videos clearly 
demonstrate that there are significant changes in the cell behavior in regard to activity of 
cell edges and dorsal surface during and after the internalizing phage entry into SKBR-3 
cells. It is well established that formation of protrusions in a variety of cells is associated 
with dynamic changes in cortical actin.  
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constant PMT, gain and offset. Figure 2-10 shows the fluorescence images of labeled F-
actin in SKBR-3 cells incubated with phage and fixed at different time points as stated 
above. F-actin in control, untreated cells was most diffusely distributed throughout the 
cell, and also thin bundles of filaments and occasional brighter granular structures were 
present. After 15 min incubation with internalizing phage, the bright granular structures 
and diffuse staining greatly diminished and thin actin bundles stain less intensely. At 30 
and 45 min of incubation, small disperse granular structures became brighter and clearly 
visible all over the cells, while thin filament bundles were still less visible than in 
untreated cells. The F-actin was further quantified using fluorescence microplate reader. 
For all the quantitative measurements, a constant number of cells (1x104) were placed in 
all the wells, treated with phage and labeled with rhodamine-phallodin. For fluorescence 
measurements, the rhodamine was excited at 560 nm and the emission was collected 
between 590-600 nm. The quantitative measurements showed significant decrease in the 
amount of polymerized actin in cells incubated with phage for 15 min, followed by 
gradual increase in F-actin content, but still remaining lower than in untreated cells 45 
min after introduction of internalizing phage into cell culture (Figure 2-11).  
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incubated overnight with cell lysate fraction. Following incubation, the resulting complex 
is pelleted by centrifugation and the proteins adsorbed to the matrix were eluted with low 
pH elution buffer. As the phage has multiple copies of binding peptides on its surface, we 
believe it can act as an affinity matrix for isolation of specific proteins. The proteins 
eluted from the matrix were separated using SDS-PAGE, resulted in the appearance of 
four bands (approximately 65, 52, 42 and 37 kDa) visualized by silver staining (as shown 
in Figure 2-12). Following SDS-PAGE separation the bands were sent for N-terminal 
protein sequencing and mass spec analysis. However, only three bands were sent for N-
terminal sequencing as the elution buffer has bovine serum albumin (BSA) and a 
corresponding band is observed at ~65 kDa. Among the remaining three bands, one 
strong and characteristic band is observed at around 52 kDa (shown in red asterisk). The 
samples were further stained with amido-black staining and excised for sequencing. The 
N-terminal protein sequencing result demonstrated it is a novel and unnamed protein. As 
the molecular weight from gel electrophoresis is relative, mass spec analysis confirmed 
the exact molecular weight is ~52 kDa. Alternatively, we are planning to obtain the 
complete sequence of the protein using peptide fingerprinting. Further experiments are 
under investigation to understand the exact nature and role of these isolated proteins.    
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2.4 Discussion 
 
There is a continuing demand for short peptide ligands such as cell internalizing peptides 
that can serve as cancer-specific diagnostic and therapeutic probes  [102]. Phage display 
has been proven to be successful in exploring protein-protein interactions  between the 
ligand and the receptor  [137]. In this work, we used landscape phage display technique 
as a tool to identify such cell internalizing peptides specific to SKBR-3 cells and 
analyzed their similarity to the natural protein ligands of the breast cancer cells. Since 
earlier studies indicated that ErbB2 is overexpressed on the SKBR-3 cancer cells  [138], 
we compared our selected peptide sequences with protein ligands and anti-ErbB2 
antibody  that bind to receptors of the ErbB family. As expected, our newly identified 
sequences show homology with natural ligands such as human EGF, amphiregulin, 
neuregulin, β-cellulin, heregulin and epigen and anti-ErbB2 antibody (Tables 2-2 and 2-
3).  Our results are also in agreement with earlier reports in which breast-tumor-binding 
peptides (SSPWSAY and YSSPTQR) were selected by using a pIII phage display library 
(C7C from New England Biolab)  [139].  Obviously, our selected sequences 
(DGSIPWST and VSSTQDFP) with highest frequency (Table 2-1) have at least four 
amino acids in common with the previously described tumor-binding peptides 
(SSPWSAY and YSSPTQR). Based on the occurrence and phage capture ELISA results 
(Table 1 and Figure 2-4), we categorize the peptides VSSTQDFP and DGSIPWST as the 
best binders to SKBR-3 cells under stringent conditions. It is remarkable that the 
73 
 
sequences of these peptides differ from the earlier discovered binding peptide sequences, 
showing that the landscape libraries used in this work can provide a more diverse 
repertoire of the cancer cell-binding probes  [118]. It is still unclear why and how the 
phages displaying VSSTQDFP and DGSIPWST (our selected cell internalizing peptides) 
can enter the SKBR-3 cells. From previous studies, proline and charged amino acids were 
found to be involved in cell internalization  [140, 141, 142, 143].  Thus one possible 
explanation could be the presence of proline residue in these peptides in conjunction with 
charged amino acid residues in these peptides.  
To further investigate the possible mechanism of phage penetration into SKBR-3 
cells, we have studied the effect of energy depletion. The phage internalization was 
abolished at 4oC (Figure 2-6 D-F) and in the presence of ATP inhibitors such as sucrose 
and sodium azide (Figure 2-6 G-I), indicating that the cellular uptake is an active process 
requiring energy supply. Our energy depletion studies and preliminary studies using 
specific inhibitors against individual cell internalization mechanisms such as 
phagocytosis, pinocytosis and endocytosis show that the phage is entering SKBR-3 cells 
through endocytosis or specifically through receptor mediated endocytosis. One possible 
reason for the internalization of phage displaying L1 or L2 sequence could be the 
intermolecular forces prevailing between the exposed peptides and amino acid residues in 
EGF receptor. There could be weak hydrogen bond formation between the side chains of 
threonine in selected peptide and asparagine residue in EGFR leading to the receptor 
mediated endocytosis. Another possibility could be the formation of hydrophobic 
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interactions between the isoleucine and phenyl alanine residues from selected peptides 
with that of leucine residues in the EGF receptor. Nonetheless, the detailed mechanism of 
phage entry displaying these peptides is still under investigation.  
While studying the possible mechanism of phage internalization we also focused on the 
actin dynamics when selected filamentous phage (L1) is internalized into SKBR-3 cells. 
We hypothesize that phage is internalized using endocytosis mechanism as stated by 
previous studies  [107].  Multiple studies indicate that actin reorganization is involved in 
the process of endocytosis  [144, 145, 146, 147, 148, 149]. We believe that in the process 
of endocytosis, when the phage comes in contact with the cell membrane receptor, 
invagination of the membrane is initiated and might result in the formation of vesicles. 
Although the contact of phage with the cell membrane is the key step in the endocytosis, 
the exact underlying mechanism is not well understood. Since one possibility could be 
the involvement of cell cytoskeleton and its associated proteins in the process of phage 
internalization, we focused our study on the actin cytoskeleton dynamics during phage 
entry into breast cancer cells. We used video microscopy followed by confocal 
fluorescence imaging to study cell behavior and visualize actin filaments before and after 
the phage entry to further our understanding of the mechanism of phage entry. We 
observed two significant changes in cell motile activity when phage is internalized into 
SKBR-3 breast cancer cells. One is the change in the behavior of the leading edges of 
SKBR-3 cells and another is the change in the dorsal ruffling of SKBR-3 cells. 
Lamellipodia, a thin protrusive structures that arise from the cell cortex undergo a 
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dynamic fluctuation at the leading edges of cells. They are protruding and withdrawing in 
rather cyclical manner in SKBR-3 cells prior to a introduction of the phage into the cell 
environment. After the introduction of the phage, the characteristic increased ruffling of 
SKBR-3 cells was observed for the duration of the experiment (45 min). This increased 
rate of the lamellipodia formation both at the cell periphery and at the dorsal surface is a 
sign of dynamic reorganization of mostly cortical actin in the cells, since it is well known 
that actin polymerization and depolymerization is a driving force for the formation of 
protrusions and the ruffling of the cell edge  [150, 151, 152, 153, 154, 155, 156, 157, 
158]. The changes in F-actin pattern of distribution   observed in fluorescence images in 
Figure 2-10 are characteristics of changes in the state of actin polymerization. 
Microspikes, filopodia and lamellipodia are shaped by dense core of actin filaments and 
changes in actin state of polymerization and distribution reflects the dynamic re-
organization of actin during phage entry.  
Inside the cell, actin exists in two forms either as polymerized helical form commonly 
known as filamentous actin or F-actin and as unpolymerized globular form known as G-
actin. In order to investigate the changes in the state of polymerization of actin during 
phage internalization, the cells were treated with phage for different times and 
immediately fixed with paraformaldehyde and incubated with rhodamine-phalloidin to 
label F-actin.  The relative fluorescence intensities of rhodamine in Figure 2-11 represent 
the amount of polymerized actin in phage treated cells. During incubation of cells with 
phages for up to 45 min we observed a net depolymerization of actin cytoskeleton in the 
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initial 15 min after the introduction of phage into the cells’ environment. Interestingly, 15 
min was the earliest time we observed phages bound to   SKBR-3 cells  using scanning 
electron microscopy in our previous study  [159]. Thus the time of increased actin 
depolymerization correlates with the time during which the process of the phage entry 
into the cells takes place. The possible rearrangement of actin in SKBR-3 cells when 
landscape phage is internalized is shown in Figure 2-8. There have been reports 
indicating that actin dynamic reorganization is involved in the entry of the Kaposi’s 
sarcoma herpes virus into endothelial cells  [160] and influenza virus into epithelial cells 
 [161]. Also it has been recently reported that the uptake of charged polystyrene 
nanoparticles into HeLa cells is mediated by the reorganization of actin  [162]. Our 
results also show that entry of filamentous phage into the SKBR-3 cells involves the 
reorganization of actin cytoskeleton and similar mechanism may be used by the phage to 
enter breast cancer cells. More detailed biochemical investigations are necessary to 
understand the possible signaling pathway/s and associated actin binding proteins 
involved in phage internalization into epithelial breast cancer cells.        
In conclusion, usage of landscape phage libraries identified new SKBR-3 breast cancer 
cell targeting or internalizing peptides (VSSTQDFP and DGSIPWST) which bind to 
SKBR-3 cells with high affinity, selectivity and specificity. These novel peptides can 
serve as targeting agents for multiple biomedical applications including targeted anti-
cancer agents, improved diagnosis and treatment purposes. 
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Chapter 3 : Synthesis and Characterization of protein-nanoconjugates 
(GNR-pVIII) for SKBR-3 breast cancer cell imaging and destruction. 
 
3.1 Introduction  
Recent advancements in nanotechnology have opened doors for novel therapeutic 
agents that can be used for early detection of cancer  [163, 164, 165]. However the 
current challenge is to understand their exact role at molecular level. Breast cancer is one 
of the most fatal cancer causing diseases  [166] and can only prevented through the early 
detection and removal of premalignant lesions. Despite the advancement of science,  
breast cancer still remains the fourth most common cancer in the United States  [47]. 
Thus, development of new approaches that are compatible with conventional methods are 
highly desirable  [167].  
Recently, photo thermal therapy involving deep penetrating near infra red (NIR) 
radiations has emerged as a promising treatment modality due to its ability to deliver 
lethal doses of heat at the target site. The desired thermal effect can be achieved by a 
suitable vector with two important capabilities: exogenous NIR absorbing ability and 
receptor binding moiety. Metal nanoparticles with excellent optical properties  [168, 169] 
are believed to be suitable candidates for photo thermal therapy  [170].  Even through 
receptor specific antibodies are good targeting source against cancer marker  they are 
limited in use by their size, cost of production and immunogenicity in an in vivo 
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environment  [171, 172]. Moreover, antibodies are limited in availability and may not 
recognize unknown receptors that over express in tumor cells. Thus, current identification 
of new cell targeting/ internalizing peptides using evolutionary selection procedure might 
serve as an alternative source for antibodies.  
Biological systems involving bacteriophage offer enhanced specificity and are 
environmentally friendly for nanomaterial synthesis  [173, 174]. Several  researchers 
have  used phage as therapeutic agent  [175] and  phage libraries  as a tool kit for 
identifying novel cell targeting ligands   [176, 177]. The primary structure of major coat 
isolated from phage libraries has three distinct domains 1) acidic N-terminus domain 
(retaining target specificity) 2) a central hydrophobic core (aids in protein-protein 
interactions) and 3) a basic C-terminus domains (electrostatically interacts with the DNA 
in native virus)  [178]. Thus, filamentous virus can be simply viewed as the assembly of 
major coat proteins onto DNA template using non covalent interactions.  
Recently, we identified new SKBR-3 cancer cell internalizing ligands using  
landscape phage libraries  [179] as described in the previous chapter. As the screened 
filamentous viruses specific to a target cancer cell has unique amino acids sequences 
displayed on their N –terminus, we hypothesize the coat proteins isolated from target 
specific phage retains its target binding nature. Also, viral proteins have multifunctional 
groups on their surface; they can be easily conjugated with nanomaterials to form next 
generation nanovectors. Taking advantage of the specificity from isolated coat proteins 
79 
 
and optical properties from nanorods, we synthesize novel nanoprobes termed protein 
nanoconjugates (GNR-pVIII).  
             
3.2 Experiments performed 
 
3.2.1 Cell culture  
Target human breast epithelial carcinoma (SKBR-3) and control normal breast 
epithelial cells (MCF-10A) were purchased from ATCC (HTB-30TM & CRL-10317 
respectively).The SKBR-3 and MCF-10A cells were cultured in Mc.Coy’s 5a modified 
medium and DMEM/F-12 medium supplemented with fetal bovine serum (10%) and 
suitable antibiotics (100 μg/ml of penicillin and 100 μg/ml streptomycin from sigma). 
Additional control fibroblasts were maintained in DMEM medium. All the cells were 
grown at 37oC in 5% CO2 and sub-cultivated for experimental procedures every 3-4 days.  
 
3.2.2. Amplification and purification of SKBR-3 specific fd-tet bacteriophage  
  Landscape phage libraries (f8/8 libraries) were obtained from Dr.Petrenko at 
Auburn University and SKBR-3 specific phage displayed with VSSTQDFP sequence on 
the N terminus of major coat protein was screened using landscape phage library as 
described elsewhere  [179]. Phage suspension was obtained by infecting starved cells (E. 
Coli k91blukan) with fd-tet bacteriophage.  40 ml of NZY medium containing 20 µg/ml 
of tetracycline was inoculated with a fresh single colony of phage-infected cells in a 250 
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ml flask. The culture was incubated under shaking at 370C and 200 rpm overnight. The 
overnight culture was then poured into a 250ml Beckman centrifuge bottle and 
centrifuged at 3000 g for 10 min at 4oC. The supernatant was poured into a fresh tube and 
centrifuged at 9300 rpm for 10 min at 4oC. The resulting clear supernatant was again 
poured into a fresh tube into which a 6 ml PEG/NaCl solution (100 g PEG 8000, 116.9 g 
NaCl and 475 ml water) was already added. The tube was kept at 40C overnight for phage 
precipitation. The precipitated phages were collected by centrifugation at 13000 rpm for 
60 min and the supernatant was removed. The pellet was then dissolved in 1 ml Tris 
buffered saline (TBS) in a micro-centrifuge tube and centrifuged again at 13000 rpm for 
10 min to remove any non dissolved material. Later, polyethylene glycol/NaCl solution 
was added and incubated overnight at 4oC. The phage precipitate was collected by 
centrifuging at 13000 rpm for 60 min using a high performance Beckman coulter 
centrifuge and the final phage pellet was resuspended in 1ml of fresh TBS. The 
concentration of phage was estimated using a UV-visible spectrophotometer at 269nm. 
 
3.2.3 Isolation of major coat protein pVIII:  
There are two different approaches to isolate major coat proteins from 
filamentous bacteriophage. One is phenol extraction method and the other is cholate 
extraction. Even though the major coat protein can be isolated using phenol extraction 
method  [180], as demonstrated in previous studies,  the cholate extraction yields a 
significant amount of α-helix structure with lower aggregation values. Therefore, we 
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adapted the cholate isolation method to obtain the cancer cell specific major coat protein. 
In this procedure, SKBR-3 specific phages were first disrupted into DNA and proteins by 
the sonication of a chloroform saturated buffer and then fractionated using sepharose 
column chromatography  [121, 181]. Briefly, 5 mL of purified phage solution (1x 1014 
virions/ml) was mixed with 10ml of 120mM cholate in 10mM Tris-HCl, 0.2mM EDTA, 
pH 8.0, and chloroform( 2.5% v/v). The mixture was incubated for 1h at 37OC with 
occasional stirring. The dissociated phage was then applied to a sepharose column and 
eluted with 10mM cholate in 10mM Tris-HCl/0.2 mM EDTA, pH 8.0, to separate the 
major coat proteins from the phage DNA. The various fractions at 1mL each was then 
collected and analyzed using a UV-Visible nanophotometer. Fractions with an 
absorbance ratio of A280/A260 greater than 1.5 were stored at 4oC for further use. The 
protein concentration was estimated using a Bradford assay and the purified protein was 
confirmed by 15% SDS-PAGE electrophoresis and western blotting.  
 
3.2.4 Synthesis of CTAB-capped gold nanorods (GNR)  
Gold nanorods (GNRs) were synthesized using an established protocol developed 
by Nikkobath et. al.  [83, 182]. First, 10 mL of seed solution was prepared in a 15 mL 
sterile centrifuge tube. In this procedure, to 9.6 mL of water 0.364 g of CTAB (0.1 M) 
was added and vortexed to form a clear solution. To this 0.425 mL of HAuCl4 (5 mM) 
was added. Later under vigorous stirring 0.6 mL of freshly-prepared ice-cold NaBH4 
solution (10 mM) was added all at once. The resulting seed solution was allowed to sit 
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for at least 1 h to ensure the excess reducing agent is reacted.  The growth solution was 
prepared in a separate 50 ml falcon tube by adding 75 μL of AgNO3 (60 mM) to 1.6 g of 
CTAB solution (0.105 M) in 40 mL water. To this solution 3.825 mL of HAuCl4 (5.886 
mM) was added and allowed to sit for 1 h. Later, 1.05 ml of HCl (1M) was added to the 
above solution and the falcon tube is gently inverted. Then 465 μL of freshly prepared 
ascorbic acid solution (0.0788M) was added, and inverted with hand. The solution 
becomes color less when ascorbic acid is added.  To this solution 112.5 μL of seed 
solution (prepared in the beginning) is added gently inverted with hands and left 
undisturbed overnight in dark. The synthesized GNRs were characterized by a UV-visible 
NIR spectrophotometer and transmission electron microscopy (TEM) measurement.  
 
3.2.5 Synthesis of polyethylene glycol (PEG) functionalized GNRs:  
For PEG modification, 3.0 mL of the above mentioned CTAB stabilized GNRs 
solution was centrifuged twice at 13,000 rpm for 20 min to remove the excess CTAB. 
The resulting pellet was resuspended in phosphate buffered saline (PBS) at pH 7.5. 
Meanwhile, a 20 µM PEG polymer (NH2-PEG-SH; molecular weight: 5000 Daltons) was 
prepared in PBS.  Later 1 mL of GNRs solution was mixed with 500 µL of PEG solution 
and incubated overnight under shaking. The following day, the solution was centrifuged 
at 13,000 rpm for 20 min and the pellet was dissolved in 1 mL of PBS (pH 7.5). The 
successful modification or coating was confirmed by UV-Visible spectrophotometer and 
Fourier transform infrared spectroscopy (FTIR). 
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3.2.6 Synthesis of protein nanoconjugates (GNR-Phage protein):  
Based on the primary structure of coat proteins as described in introduction, the 
isolated protein has three distinct regions: 1) an acidic N-terminus with the cancer cell 
specific peptide exposed outside (1-20 amino acids), 2) a central hydrophobic core which 
aids in protein-protein interactions in the native virus (21-39 amino acids) and 3) a basic 
C-terminus with four lysine residues that are actively involved in forming electrostatic 
interactions with the DNA backbone in the native virus  [178]. Since the foreign peptide 
specific to the target cancer cell is present on the N (amino)- terminus end, it is protected 
with a blocking agent and the carboxyl group on the C-terminus is utilized to form a 
covalent bond with the amino group of PEG in functionalized nanorods. Briefly, the N-
terminus of the protein was first blocked with tert-Butyl carbamate (BOC) and 
carbodiimide (EDC) chemistry was used to form a covalent bond between the carboxyl 
terminus of the protein and the amino functionalized gold nanorod (GNR-PEG). There 
are four major steps involved in the synthesis of GNR-Phage protein complex. They are 
protection (BOC), activation (EDC/NHS), conjugation with nanorods (PEG 
functionalized nanorods) and deprotection (removal of BOC).  We termed the resulting 
complex as protein-nanoconjugate (GNR-pVIII) or hybrid nanoconjugate. The schematic 
diagram of the protein-nanoconjugate (GNR-pVIII) is shown in Figures 3-1. In this 
procedure, 1 mL of protein (1.12 mg/mL determined from spectroscopic measurements 
A280) was treated with 2.1 µl of BOC and incubated for 2-6 hrs. Then, the carboxyl 
terminus of the protein was activated with 50 µL of EDC (0.3 mg/mL) and 25 µL of NHS 
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(0.2 mg/mL). To synthesize protein-nanoconjugate (GNR-pVIII) with covalent 
interactions, 20µL of activated pVIII protein was added to 1 mL of GNR-PEG solution in 
an eppendorf tube and incubated for 30 min under oscillation. After incubation, the 
mixture was centrifuged twice at 13,000 rpm to remove any unbound pVIII protein and 
finally re-suspended in phosphate buffered saline, PBS (pH 7.4). The resulting protein-
nanoconjugate is found to be stable at 4 ºC for up to 2 weeks. Finally, the BOC is 
unprotected using mild acidic conditions. The successful modification was confirmed by 
UV-Visible spectrophotometer and Fourier transform infrared spectroscopy (FTIR).  
 
3.2.7. Binding studies (GNR-Phage protein complex)  
The binding affinity between the phage proteins and the PEG functionalized gold 
nanorods were determined using a fluorescence spectrophotometer with constant protein 
concentration (A<0.05) and varied GNR-PEG concentration (0 – 2X10-12M). The 
intrinsic fluorescence of protein from tryptophan residues were excited at 280 nm and the 
emission was collected between 300-400 nm.  
The binding and  dissociation constants were calculated based on the following 
equation which is slightly modified from the previously reported formulae  [183].  
                                           F0-F/F-F∞ = (GNR/Kdiss)n             (equation 1) 
The binding constant, Kb, was obtained by plotting log (F0-F)/(F-F∞) versus log (GNR), 
where F0  and F∞ are the relative fluorescence intensities of tryptophan from protein 
alone and the protein saturated with  GNRs, respectively.  
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3.2.8 Cytotoxicity (MTT assay) and serum stability measurements  
The cytotoxicity of the synthesized nanoconjugates were evaluated by measuring 
the metabolic activity of the cells  by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide assay (MTT assay) as described before  [184, 185]. The results were 
expressed as percentage cell viability. Briefly, the target and control cells were cultured 
in a 96 well plate and incubated with different concentrations (0.2µM- 0.2nM) of GNRs, 
GNR-PEG, GNR-PEG-pVIII complexes for different time points (1h, 6h, 24h and 36h). 
After specified incubation, the cells were completely washed and treated with 50 µL of 
MTT reagent (5 mg/ml) and incubated for 4 h at 37oC. After the incubation, the cell were 
thoroughly washed with PBS and treated with 100 µL of DMSO treatment. Later, the 
amount of color developed was measured using plate reader at 570nm and cell viability 
was calculated as a percentage viable cell in comparison to control untreated cells.  To 
further verify the stability the nanoconjugates were centrifuged and dissolved in two 
different solvents (PBS and Serum) and the UV-Visible spectrum was measured to 
confirm its stability. TEM section cutting was performed to confirm the entry of GNR-
pVIII into SKBR-3 cells. 
 
3.2.9 Specificity, Imaging and Photo thermal destruction studies  
Three different cell lines, namely SKBR-3 cells, MCF-10A cells and fibroblast, 
were incubated with GNRs, GNR-PEG and GNR-pVIII conjugates and tested for 
specificity, imaging and photo thermal destruction abilities. Briefly, stock solutions of 
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gold nanorod and protein conjugates which are stored at 4oC, are brought to room 
temperature and diluted with medium before incubation with target and control cell lines. 
The cells were rinsed with D-PBS and incubated with gold nanorods and nanoconjguates 
having an optical density of 0.5 at 370C for 30 min. As a control, free PBS without 
nanorods was added. After incubation, the unbound nanorods were removed by rinsing 
thoroughly with PBS. In case specificity experiments, the cells were fixed with 4% para 
formaldehyde in PBS and incubated for 15 minutes at 37oC. Later the buffer containing 
the fixative was removed and cells were rinsed twice in PBS. Then the cells were 
permeabilized with 0.1% triton x-100 and incubated for 2 min. After incubation period 
the cells were washed three times with PBS and incubated with anti pVIII antibody for 
1hr. Rinsed thoroughly and labeled with IgG conjugated rhodamine for 1h.  The non 
specifically bound dye is removed by repeated washes and the cells nuclei were counter 
stained with DAPI for 5 min and mounted on a microscope slide. The cells were 
examined using a Nikon Eclipse Ti inverted fluorescence microscope system. For 
imaging purposes, the cells were cultured on cover glasses and incubated with conjugates 
as described above, washed thoroughly to remove non specifically bound nanorods, fixed 
in 4% para formaldehyde in PBS and mounted on a microscope slide. The slides are 
directly viewed under a dark field microscope to get the back scattered images. For photo 
thermal therapy (PTT) experiments, the cells were incubated as described above and 
thoroughly washed. Later, the target and control cells were exposed to NIR (near infra 
red) light using a continuous wave (CW) laser at 808nm. The power densities were varied 
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from 0.079 W/cm2 to 5 W/cm2. The live and dead cells were analyzed using a viability kit 
(calcein AM and Ethidium homodimer live/dead viability/ kit for mammalian cells from 
Molecular Probes). The data obtained was further quantified according to the 
manufacturer’s instructions. All the statistical analysis was performed using student’s t-
test.  
 
3.2.10 Live imaging of SKBR-3 cells treated with protein-nanoconjugates  
SKBR-3 cells cultured on 25-mm cover glasses as described above were 
transferred to a perfusion filming chamber just before filming. The chamber was placed 
on the stage of a Zeiss Standard microscope enclosed in a plastic bag and the temperature 
was maintained at 37oC with an air curtain incubator (Sage Instruments). Digital images 
of live cells were recorded every 10 seconds. Cells were recorded for 15 min in McCoy’s 
5A modified medium and then for 70 min using only a GNRs solution (without protein) 
and a nanoconjguate (GNR-pVIII) solution. These solutions were perfused into the 
chamber using a 2.5-cc syringe driven by a syringe pump (Sage Instruments model 
341A). Frame-by-frame analysis was performed using the software (Videos can be found 
in the original manuscript as separate files).  
 
3.2.11 Gene expression studies using microarray  
In order to explore the cascade of molecular interactions during protein-
nanoconjugates incubation with our model SKBR-3 cells, we compared the 
88 
 
transcriptional profile of untreated SKBR-3 cells to that of cells treated with 
nanoconjugates. SKBR-3 cells were incubated with nanoconjugates for 6 h and washed 
thoroughly with PBS.  The RNA from the untreated SKBR-3 cells as well as from the 
GNR-pVIII treated cells was isolated using an RNeasy Kit (Qiagen, USA) according to 
the manufacturer’s instructions. All of the experiments were performed in triplicates. The 
quality control check (as shown in Figure 3-14), cDNA preparation, array hybridization 
and scanning was performed by the Oklahoma Medical Research Foundation (OMRF) 
microarray research core facility.  The Illumina WG-6_v3 arrays targeting >48,000 
transcripts and variants were used in triplicates for each experimental condition.  
3.2.12 Microarray Data analysis  
The Illumina WG-6_v3 array data for each experimental condition was exported 
from BeadStudio Software for further analysis. The data was normalized as described 
previously  [186, 187], using the variability of lowly expressed genes as a reference 
point. In order to find genes expressed above the level of technical noise, a frequency 
histogram of raw expression values was examined for each array. The histogram yielded 
a right-skewed unimodal distribution curve with the mode around 75.  A normal 
distribution curve representing the variability of the data around zero was then fitted 
around the mode, mirroring the Gaussian profile of the left part of the histogram. Its 
parameters were then defined (mean, SD) and the data were normalized to the standard 
deviation of the noise after subtraction of the mean. The arrays were then Log10-
transformed and adjusted to each other by robust linear regression under the assumption 
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that the expression of most genes does not change. The data was then filtered to remove 
genes with an expression value less than 3.0. This is equivalent to setting a threshold at 3 
SD above the noise level. Genes expressed below the noise level under all experimental 
conditions (about 1,600) were excluded from consideration, as their expression cannot be 
reliably assessed. Full microarray data were deposited in the Gene Expression Omnibus 
(GEO, GSE23118) and are accessible on the GEO web-site. 
To identify differentially expressed genes between two experimental groups, we 
used  associative analysis as described by Dozmorov et al.  [187].  Briefly, in pooled 
microarray datasets, a reference group of genes expressed above background with a low 
variability of expression was identified by an F-test.  The assumption is that because most 
genes do not change expression in any experiment, the variability of expression among 
the group is due to random, technical factors alone. Genes with statistically significantly 
variability above the random, technical variation are assumed to vary for biological 
reasons. A t-test, termed "associative t-test," was applied to test if a given gene belongs to 
or differs from the group.  The associative t-test is a standard t-test applied to compare 
the expression variability rather than differences in mean values.  To identify an 
evaluable number of differentially expressed genes, a stringent criterion was applied.  
Only genes expressed below noise level in one group and greater than 5 SD above noise 
level in another group were selected for further analysis.  For genes that were expressed 
above noise level in both conditions, as well as those that have greater than 1.5-fold 
differences in expression levels and expressed greater than 10 SD above noise level in at 
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least in one condition were also selected.  These genes can be considered as “beacons” 
that point to pathways or gene networks that are altered. 
To classify each group of genes in more detail by their ontological properties, we 
used the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
 [188]. The Gene Functional Classification tool in DAVID builds clusters of genes with 
significantly similar ontologies as tested against an entire list of genes in the Illumina 
WG-6_v3 array. Medium stringency was used to yield a comprehensive set of ontological 
groups and to group genes with similar functions. Increasing or decreasing stringency 
resulted in the identification of fewer or more groups of genes with similar functions but 
did not produce any additional information. 
Lists of genes from individual clusters were submitted to Ingenuity Pathway 
Analysis (IPA; Ingenuity® Systems, Redwood City, CA, http://www.ingenuity.com). 
Ingenuity maps gene IDs to a database and performs statistical computing to identify the 
most significant ontologies, canonical pathways, and networks overrepresented in a given 
gene list as compared with the entire list of genes in the Illumina WG-6_v3 array. By 
default p<0.05 was used in all calculations. Gene lists from each group were analyzed for 
overrepresented general functions, canonical pathways, and the networks that can be 
assembled from them. 
 
3.2.13 In vivo feasibility experiments 
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3.2.13.1 Mice housing  
All the animal experiments were conducted according to the guidelines provided 
by Institutional Animal Care and Use Committee (IACUC), University of Oklahoma, 
Norman campus. Nude mice of 3 to 5 weeks age (n=50), weight (15.67 ±2.09g) (Mean ± 
SD), weight ranged from 9.7g to 19.4g, purchased from Jackson laboratories  were 
housed in a special caged ventilators for animal care.  Mice were feed with standard mice 
food and bedding was changed twice a week. Body weight and tumor size was measured 
weekly.  All the animal experiments were done in collaboration with our post doctoral 
fellows Dr. Kay Guo and Dr. Zipeng Zen. 
 
3.2.13.2 Development of in vivo breast tumor model  
Once the SKBR-3 cells reached 90% confluence and harvested, they are re 
suspended in serum and antibiotics free Mc. Coy’s medium at a concentration of 1×107 
cells/ml. In order to inject the cancer cells into the nude mice , skin was sterilized using 
70% ethanol, and then 1×106 cells/side in 0.1 ml Mc. Coy’s medium were injected into 
the back of mice under skin on either sides. After 2-3 weeks of SKBR-3 cells injection, 
the tumors were visible to the naked eye and the size of the tumor was measured from 
cross-sectional area (length/2 × width/2 × π) using a digital caliper. After two-three 
weeks, when the tumor size was reached to 25mm2 the mice is chosen for experiments. 
The tumor developed was confirmed using hematoxylin and eosin staining (H & E).  
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3.2.13.3 In vivo Specificity and Imaging studies  
Once the tumor presence is confirmed by using H & E staining, three mice were 
chosen for specificity experiments. As a control one mouse was injected with 150 μl of 
PBS. The other two mice were injected with 150 μl of GNR and protein-nanoconjugates 
(GNR-pVIII)  solutions respectively. The nanoparticles were allowed to circulate for 24 h 
and the following day the animal was sacrificed and the tumor is excised for immune-
histochemcial studies. For immune labeling, the tissue sample is embedded in paraffin 
and cut into 5 micron thick slice using microtome and mounted on a positively charged 
slide. The slides were dried at room temperature overnight to remove water that is 
trapped under the tissue. Later, the slides are deparaffinized and rehydrated by placing 
them in the beaker in the following order : xylene for 5 minutes each (twice) ; xylene: 
ethanol (1:1) for 5 minutes (once) ; 100% ethanol for 5 minutes each (twice); One time 
with 95% ethanol for 5 minutes;  one time with 70 % ethanol for 5 minutes; one time 
with 50 % ethanol for 5 minutes. Finally the slides are rinsed under running cold tap. 
(Slides should not be dried from this point). Later, the antigens were retrieved using 
enzymatic method and continued for immune staining. For primary antibody labeling the 
slides are washed twice with TBS- 0.02% Triton x-100 and blocked in 10% serum with 
1% BSA in TBS for 2 hours at room temperature and then primary antibody (anti pVIII 
antibody) diluted in TBS with 1% BSA was added and incubated overnight at 4oC. After 
incubation, the slides are rinsed with TBS-0.025% Triton under gentle agitation and 
diluted secondary antibody conjugated to fluorescent dye (IgG-rhodamine) was added 
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and incubated for 1 hour at room temperature. Finally, the slides are rinsed with TBS and 
tissue is counter stained with DAPI and cover sliped. 
 
3.3 Results 
3.3.1 Surface modification of protein-nanoconjugates  
Earlier reports suggest that the wavelength shift in SPR or UV-Visible spectrum 
of gold nanoparticles is linear with the change in refractive index induced by the 
absorbate layer  [189]. Hence, a UV-Visible spectrum is used to examine the possible 
surface layer coating on GNRs. The scheme of protein-nanoconjugate synthesis is shown 
in Figure 3-1.  The isolated major coat protein used in this study was characterized by gel 
electrophoresis and western blotting as shown in Figure 3-2. Here, we synthesized 
nanorods (coated with phage protein) with an aspect ratio of 4.01 and absorption 
overlapping in the near infra red region with the laser (808 nm) in our lab. Here, the 
phage protein is bound to PEG functionalized gold nanorods using carbodiimide 
chemistry. The successful synthesis of the conjugates was confirmed by using TEM and 
UV-visible spectrophotometer. The electron microscope imaging shows the nanorods are 
uniform in size and monodispersed and not aggregated upon surface coating with phage 
protein (Figure 3-3 A-B). In order to visualize the protein bound to nanorod surface, the 
samples are negatively stained. The light background on the dark nanorod surface in 
Figure 3-3 (B) might be the protein coated on the nanorod surface. The synthesized gold 
nanorods exhibits two surface Plasmon absorption bands one strong  wavelength band 
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~760nm corresponding to longitudinal oscillation of electrons and other weak band 
~525nm corresponding to the transverse oscillation of electrons. Figure 3.3 (C) shows the 
absorption profiles of synthesized GNR coated with PEG and nanorod coated with phage 
protein. Because the λlong (longitudinal SPR band) is systematically red shifted upon the 
successive coating with the coat protein, we believe the conjugation is successful. The 
amount of phage protein bound to the functionalized nanorods is measured either by 
theoretically calculating the amount of free protein present in the nanoconjugate sample 
or by using standard protein determination methods (bicinchoninic acid). By precipitating 
the GNR-PEG-pVIII complex in PBS, we could separate unbound protein on 
functionalized GNR. Thus the phage protein self assembles to form targeted 
nanoconjugates without any further modifications. Here, PEG is not only used as a linker 
to conjugate protein but also used to enhance the in vivo circulation of these particles.  
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3.3.2 Affinity, stability, biocompatibility and cell internalization studies of 
nanoconjugates:  
As the binding of phage protein to nanorod surface influence their distribution in 
the cells or tissue, it is important to understand the affinity of protein on the nanorod 
surface. Hence, the GNR binding to phage protein is estimated using a fluorometric 
method. Changes caused by different concentrations of GNR are shown in Figure 3-4, the 
fluorescence emission spectra of phage protein. As expected we observed a fluorescence 
quenching when protein was bound to the gold nanorod surface. This could be due to a 
complex formation between the GNR and phage protein. Further analysis of data  using 
double log plot as shown in Figure 3-4 reveals the binding constant of nanorods coated 
with phage protein is Kb= 1.2 x 109 M-1. This show the affinity between the protein and 
the nanorod is very high. 
In order to understand the stability of various nanoconjguates in serum, we used 
UV-Visible spectrophotometer to study the aggregation behavior of the synthesized 
nanoconjugates. As shown in Figure 3-5 no obvious change in the UV-visible spectra of 
nanoconjugates was observed when the synthesized nanoparticles are transferred from 
PBS to serum. Instability indicates flattening of the peak. Since, there is no flattening, it 
confirms the stability of various nanoparticles in serum and their potential use for in vivo 
applications.  
The cytotoxicity of nanoconjguates was studied by using MTT assay. Figure 3-6 
shows the viability of SKBR-3 cells grown for 24 h in the presence of nanoparticles at a 
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concentration of 40 μM. Except gold nanorods, other conjugates are found to be non 
toxic to SKBR-3 cells at this particular concentration. This toxicity of GNR may be due 
to the presence of cytotoxic CTAB on its surface. The concentration of nanoparticles 
used for cytotoxic measurements are much higher than the concentration used for 
performed specificity, imaging and photo thermal experiments.  
Cell internalization studies were performed using TEM section cutting. As shown 
in Figure 3-7 the ultra microtome thin sections of SKBR-3 cells and examination under 
transmission electron microscopy confirmed the internalization of protein nanoconjugates 
with in the cells.  
The amount of nanorods uptake into our target SKBR-3 cells was measured by 
incubation at different time points (15min, 1h and 6 h). For these studies, the phage 
protein is replaced with fluorescently labeled (FITC) synthetic peptide containing the 
same target SKBR-3 cells binding sequence to that of phage protein. As shown in Figure 
3-8 the uptake was observed to be high at 6 h incubation and no characteristic uptake is 
noticed at 15 min incubation time. Also, we did not observe any significant difference in 
the fluorescent signal at much higher time points in comparison to 6 h.   
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3.3.3 Specificity, Light Scattering and Photo thermal therapy using protein coated 
nanorods (GNR-pVIII) on mammalian cells:  
In vitro evaluation was performed to demonstrate the target specificity, imaging 
and photo thermal destruction of our novel protein nanoconjugates. Three different cell 
lines namely SKBR-3 cells, MCF-10A cells and fibroblast cells were incubated with 
nanoconjugates and the specificity was tested using indirect fluorescent labeling against 
phage protein present in the nanohybrid. As the GNR-pVIII has phage protein, we 
hypothesized mammalian binding to these nanoconjguates can be labeled with anti pVIII 
antibody. All the cells were counterstained with DAPI. From the fluorescence immune 
labeling (as shown in Figure 3-9), the binding of protein nanoconjugates (GNR-pVIII) to 
the target SKBR-3 cells is remarkably different to that of other control normal breast cells 
(MCF-10A) and fibroblast. This confirms the binding of our novel nanoconjugates to 
target SKBR-3 breast cancer cells. 
Dark -field microscopy is used to analyze the light scattering of nanoconjugates 
from target and control cell lines. In this method, a narrow beam of white light is passed 
through the samples. Previous studies show different nanoparticles scatter different 
colored light under dark field based on their size and shape  [190] .  Because of the 
presence of strong longitudinal surface Plasmon oscillation with a frequency in the NIR 
region, protein-nanoconjugates exhibit strong light scattering in target SKBR-3 cells as 
expected (Figure 3-10). The high scattering in Figure 3-10 is correlated with areas 
containing gold nanorods. By contrast, control normal breast cells (MCF-10a) and 
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fibroblast showed little or no light scattering from gold nanorods. As the protein bound 
on the nanorod surface is specific to SKBR-3 cells, we believe protein coated nanorods 
bind specifically to target SKBR-3 breast cancer cells and gave them a distinguished back 
scattering from other control cells. This confirms the use of our nanoconjugates for 
imaging applications.  
Previous studies showed that gold nanorods can act as strong photo thermal 
absorbers for destroying harmful cells. In order to test the cell destruction ability, the 
cells were incubated with nanorods which exhibited characteristic SPR absorbance band 
around 808nm and exposed to near infra red (NIR) radiations using 808nm laser 
radiations. Here, the target and the control cells were incubated with various 
nanoconjugates for 30 min and are exposed to different laser powers for 5 min, and the 
viability of the cells was verified using fluorescence microscope. Our optimized 
conditions showed exposure to laser at 808nm and 0.079 W/cm2 power density in the 
presence of GNR-pVIII caused photo destruction of target cancer cells alone and no 
significant death is observed in control cells as detected by live/dead cell viability kit as 
shown in Figure 3-11.  Increasing the power to 20 W/cm2 resulted in the death of target as 
well as normal cells. Thus, by conjugating nanorods with phage protein that can 
selectively bind to target malignant cells, the cells can be photo thermally destroyed with 
very less energy than required to kill the normal health cells. Further quantitative analysis 
revealed around 60% of the target cells are dead when treated with protein 
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3.3.4 Cell behavior using video microscopy:  
In order to explore the morphological changes during GNR-pVIII uptake into target 
SKBR-3 cancer cells, we performed live cell video imaging. Interestingly, we observed 
significant changes in the membrane ruffling when unmodified gold nanorods were incubated 
with SKBR-3 cells (Figure 3-12). However, such drastic changes are not observed when protein 
coated nanorods (GNR-pVIII) are incubated with target cells (Figure 3-13). Unlike significant 
membrane retraction towards the center in case of GNR alone treated cells, we observed SKBR-3 
cells are sufficed to induce membrane ruffling during protein coated nanorods incubation which 
might indicates the cellular response is mediated through cytoskeleton. GNR-pVIII showed 
minimal abrupt cell changes when compared to GNR alone treatment where active cells 
are withdrawing their contacts with neighbouring cells and in some places the cells are 
rounding up. This may be due to the cytotoxicity of the CTAB present around GNR, 
where as such behavior is not observed in GNR-pVIII treated SKBR-3 cells. Since 
majority of live cells treated with GNR-pVIII studied by digital videomicroscopy showed 
increased activity at their edges, we believe that GNR-pVIII are taken into the SKBR-3 
cells using actin mediated endocytosis. Our lab is currently performing more detailed 
research to understand the cell biology aspects during GNR-pVIII treatment. 
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Lysosome activation, heparin binding, and response to inorganic substances were 
the most significant ontologies affected by GNR-pVIII internalization (Table 3-3). 
Heparin binding may represent the main mechanism by which cells recognize phage 
peptide bound to gold nanorods. Interestingly, Heparin-coating has been proposed as a 
non-toxic way of delivering nanoparticles into the cells  [191, 192], reflecting our 
observations of non-cytotoxicity of GNR-pVIII. Heparin binding nanostructures have 
been shown to promote growth of blood vessels  [193], and ANG (angiogenin) was one 
of the genes upregulated by GNR-pVIII treatment. Best known for its angiogenesis-
promoting properties, it also possesses heparin- and actin binding activity. Once bound, 
angiogenin is endocytosed and translocated to the nucleus, thereby promoting the 
endothelial invasiveness. Angiogenin activation may indicate increased endothelial 
permeability upon GNR-pVIII treatment and enhanced GNR-pVIII delivery as a 
consequence. VTN (vitronectin) is another heparin binding, cell adhesion and spreading 
factor found in serum and tissues. Vitronectin interact with glycosaminoglycans and 
proteoglycans and is recognized by certain members of the integrin family and serves as a 
cell-to-substrate adhesion molecule. As such, it may act in concert with angiogenin in 
GNR-pVIII internalization process. Another gene in this category, APOE (apolipoprotein 
E), has been found to mediate binding, internalization, and catabolism of lipoprotein and 
nanoparticles  [194]. APOE was present in another category; response to inorganic 
Substance, along with OLR1 (oxidized low density lipoprotein (lectin-like) receptor 1). 
OLR1 is a receptor that mediates the recognition, internalization and degradation of 
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oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. 
These molecules appeared in a single network of genes affected by GNR-pVIII (Figure 3-
15B), and appeared as main sensors for GNR-pVIII recognition and internalization via 
binding to heparin-like gylcosaminoglycans.  
The most significant ontology represented by four genes was Lysosome. 
Activation of lysosomes membrane-limited organelles responsible for degradation of 
macromolecules has been observed upon cell exposure to nanoassemblies  [195, 196]. 
We hypothesize that activation of lysosomes may represent cellular attempt to degrade 
internalized GNR-pVIII.  
Antigen Presentation Pathway was the most significant canonical pathway 
affected by GNR-pVIII internalization, followed by Neuregulin Signaling and Virus 
Entry via Endocytosis (Table 3-4). Since GNR-pVIII contain bacteriophage peptide it 
was not surprising that Antigen Presentation Pathway and endocytotic virus entry were 
the most overrepresented. Specifically, two members of Major histocompatibility 
complex (MHC) class I molecules (HLA-A and HLA-K) were highly upregulated upon 
GNR-pVIII treatment, with other members being upregulated slightly below the 
threshold for statistical significance. Interestingly, no change in expression of MHC class 
II molecules was observed, implying that target cells act as non-professional antigen 
presenting cells upon GNR-pVIII exposure. MHC class I molecules present degradation 
products derived from intracellular proteins in the cytosol. Harnessing this pathway has 
been proposed as a method of delivery of cancer vaccines using nanoparticles  [197]. 
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Activation of MHC class I signaling through HLA-A and HLA-K receptors appeared to 
complement aforementioned lysosome activity and processing of internalized GNR-
pVIII.  
Some intracellular or viral proteins, as well as nanoparticles, are processed by a 
proteasome  [198] whose members include proteasome subunit, beta type, 8 (PSMB8, 
aka large multifunctional peptidase 7), and upregulated in response to GNR-pVIII. The 
activated proteasomes are translocated into the endoplasmic reticulum by the transporter 
associated with antigen processing (TAP). Both TAP1 and TAP2 were also upregulated 
in response to GNR-pVIII. An essential function of a modified proteasome, the 
immunoproteasome, is the processing of class I MHC peptides. This suggest that MHC 
class I molecules may be responsible for recognition of GNR-pVIII within a cell via 
proteasome-mediated processing. 
A prominent group of seven members of G antigen family of genes were 
identified as upregulated by GNR-pVIII treatment. These molecules by their antigen 
nature appeared to fit to the picture of MHC class I signaling, but were excluded from the 
analysis due to lack of annotation. G antigens may represent a unique mechanism of non-
cytotoxic GNR-pVIII recognition by cells and currently are under investigation in our 
lab. 
Neuregulins are members of EGF family of growth factors and are ligands for the 
ErbB receptors. Since SKRB-3 cells express receptors for epidermal growth factors 
 [199] and selection of peptide for nanoconjugate construction was performed with high 
113 
 
affinity to these receptors up regulation of neuregulin signaling appeared as a logical part 
in SKRB-3 cell line treated with GNR-pVIII. The major pathways involved in 
neuregulin’s signal transduction include the Ras- and Shc-activated MAPK pathway, the 
PI3K-activated AKT pathway, the JAK/STAT pathway and the PLC-γ pathway, which 
ultimately affect cell proliferation and migration (both associated with tumorigenesis), 
adhesion, differentiation and apoptosis. These molecules appeared as parts of a single 
network built from up- and downregulated genes (Figure 3-15 B). This network 
highlights APOE-mediated signaling, activation of HLA-A and OLR1 receptors, 
upregulation of AKT complex and proteosomal parts integrated through IRS1 and LDL 
with kinase signaling. Interferon alpha connected signal transduction to the nucleus 
culminating in activation of STAT5A transcription factor and NFkB complex. Genes 
from lysosome (IFI27) and proteasome (PSMB8) ontologies were also regulated by 
Interferon alpha. Interestingly, although ErbB2 gene did not change its mRNA expression 
it was included in the network as another master regulator of the downstream signaling. 
Members of G antigen family were not present in the network due to lack of their 
interaction information. 
Nanoassemblies similar to GNR-pVIII have been used to increase drug delivery 
into tumors. However, such delivery is often associated with cytotoxicity of normal cells 
 [195]. The distinctive feature of GNR-pVIII is that no activation of cytotoxic pathways 
was observed. This makes GNR-pVIII an ideal model for imaging and targeted delivery 
of drugs into tumors.  
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Table 3-2: Genes up-regulated in SKBR-3 cells in response to protein coated 
nanorods 
PROBE_ID SYMBOL DEFINITION 
ILMN_1740938 APOE apolipoprotein E (APOE). 
ILMN_1726388 ACBD7 PREDICTED: acyl-Coenzyme A binding domain 
containing 7 (ACBD7). 
ILMN_1760727 ANG angiogenin, ribonuclease, RNase A family, 5 (ANG), 
transcript variant 2 
ILMN_1780170 APOD apolipoprotein D (APOD). 
ILMN_1782057 ATP8B2 ATPase, class I, type 8B, member 2 (ATP8B2), 
transcript variant 1. 
ILMN_1712608 BFSP1 beaded filament structural protein 1, filensin (BFSP1). 
ILMN_1723480 BST2 bone marrow stromal cell antigen 2 (BST2). 
ILMN_1772074 C19orf51 chromosome 19 open reading frame 51 (C19orf51). 
ILMN_1733288 C1RL complement component 1, r subcomponent-like 
(C1RL). 
ILMN_1689585 C20orf194 chromosome 20 open reading frame 194 (C20orf194). 
ILMN_1806488 CCDC108 coiled-coil domain containing 108 (CCDC108), 
transcript variant 1. 
ILMN_1758778 CEP110 centrosomal protein 110kDa (CEP110). 
ILMN_1696537 DDIT4L DNA-damage-inducible transcript 4-like (DDIT4L 
ILMN_1669376 DRAM damage-regulated autophagy modulator (DRAM). 
ILMN_1705035 FBXL7 F-box and leucine-rich repeat protein 7 (FBXL7). 
ILMN_1778144 FLJ20489 hypothetical protein FLJ20489 (FLJ20489). 
ILMN_1671482 GALM galactose mutarotase (aldose 1-epimerase) (GALM). 
ILMN_1671054 HLA-A major histocompatibility complex, class I, A (HLA-A). 
ILMN_2203950 HLA-A major histocompatibility complex, class I, A (HLA-A). 
ILMN_2165753 HLA-A29.1 major histocompatibility complex class I HLA-A29.1 
(HLA-A29.1) 
ILMN_2092850 HPSE heparanase (HPSE). 
ILMN_1766499 HSPA2 heat shock 70kDa protein 2 (HSPA2). 
ILMN_2058782 IFI27 interferon, alpha-inducible protein 27 (IFI27). 
ILMN_1784178 IFT172 intraflagellar transport 172 homolog (Chlamydomonas) 
(IFT172). 
ILMN_2334296 IL18BP interleukin 18 binding protein (IL18BP), transcript 
variant A. 
ILMN_1759232 IRS1 insulin receptor substrate 1 (IRS1). 
ILMN_1702385 LILRA4 leukocyte immunoglobulin-like receptor, subfamily A 
(with TM domain), member 4 
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ILMN_1767665 LOC493869 similar to RIKEN cDNA 2310016C16 (LOC493869). 
ILMN_1674097 LOC645037 similar to GAGE-2 protein (G antigen 2) (LOC645037). 
ILMN_1674710 LOC647784 PREDICTED: hypothetical protein LOC647784, 
transcript variant 1. 
ILMN_2391891  MAP2K5  mitogen-activated protein kinase kinase 5 (MAP2K5), 
transcript variant A.
ILMN_2071809  MGP  matrix Gla protein (MGP).
ILMN_1653278  MUC20  mucin 20, cell surface associated (MUC20), transcript 
variant S.
ILMN_2370091  NGFRAP1  nerve growth factor receptor (TNFRSF16) associated 
protein 1
ILMN_2347592  NMB  neuromedin B (NMB), transcript variant 1. 
ILMN_1757019  NTN4  netrin 4 (NTN4).
ILMN_1723035  OLR1  oxidized low density lipoprotein (lectin-like) receptor 1 
(OLR1).
ILMN_1790106  PLP1  proteolipid protein 1 (Pelizaeus-Merzbacher disease, 
spastic paraplegia 2, uncomplicated) (PLP1), transcript 
variant 2.
ILMN_1787509  PRIC285  peroxisomal proliferator-activated receptor A interacting 
complex 285 (PRIC285), transcript variant 2. 
ILMN_1771538  PSCA  prostate stem cell antigen (PSCA).
ILMN_1767006  PSMB8  proteasome (prosome, macropain) subunit, beta type, 8 
(large multifunctional peptidase 7) (PSMB8), transcript 
variant 2.
ILMN_2390299  PSMB8  proteasome (prosome, macropain) subunit, beta type, 8 
(large multifunctional peptidase 7) (PSMB8), transcript 
variant 1.
ILMN_1713829  PTGES  prostaglandin E synthase (PTGES).
ILMN_2042771  PTTG1  pituitary tumor-transforming 1 (PTTG1). 
ILMN_1709795  RAC2  ras-related C3 botulinum toxin substrate 2 (rho family, 
small GTP binding protein Rac2) (RAC2). 
ILMN_1701613  RARRES3  retinoic acid receptor responder (tazarotene induced) 3 
(RARRES3).
ILMN_1709683  RASSF2  Ras association (RalGDS/AF-6) domain family 2 
(RASSF2), transcript variant 2.
ILMN_1654398  RGL1  ral guanine nucleotide dissociation stimulator-like 1 
(RGL1).
ILMN_1753547  STAT5A  signal transducer and activator of transcription 5A 
(STAT5A).
ILMN_1804663  THBS3  thrombospondin 3 (THBS3).
ILMN_1741768  TMPRSS3  transmembrane protease, serine 3 (TMPRSS3), 
transcript variant D.
ILMN_1809842  TNNC1  troponin C type 1 (slow) (TNNC1).
ILMN_1782295  TRPC4  transient receptor potential cation channel, subfamily C, 
member 4 (TRPC4).
ILMN_1747546  TSPAN1  tetraspanin 1 (TSPAN1).
ILMN_1657554  TSPYL2  TSPY-like 2 (TSPYL2).
ILMN_1691127  VTN  vitronectin (VTN).
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Table 3-3: Overrepresented functions among upregulated genes in protein coated 
nanorods treated SKBR-3 cells. 
 
 
 
 
 
 
 
Table 3-4. Genes and canonical pathways overrepresented in protein coated 
nanorods treated cells. Bold highlights up regulated genes, regular font marks down 
regulated genes. 
 
 
Canonical Pathways Molecules p-value 
Antigen Presentation Pathway HLA-K, HLA-A, PSMB8 0.0005 
Neuregulin Signaling RAC2, STAT5A, HSP90AA1 0.0071 
Virus Entry via Endocytic Pathways RAC2, HLA-A 0.05 
 
 
 
 
 
 
ILMN_1800317  WNT5A  wingless-type MMTV integration site family, member 5A 
(WNT5A).
ILMN_1771093  ZNF414  zinc finger protein 414 (ZNF414).
ILMN_1836309    PREDICTED: LOC440151 (LOC440151) 
Functional category Molecules p-value 
Lysosome IFI27, DRAM, TSPAN1, 
SLC48A1 
0.009 
Heparin binding ANG, APOE, VTN 0.032 
Response to inorganic substance APOE, MGP, OLR1, TNNC1 0.028 
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3.3.6 In vivo tumor development and specificity experiments 
 
As the nude mouse is deficient in thymus, it is able to take the epithelial cells 
from human origin. Thus, SKBR-3 epithelial breast cancer cells are injected into nude 
mice and a tumor model is developed. The developed tumor is physically and 
microscopically characterized. As shown in Figure 3-16 (A, B) the nude mice before and 
after tumor development is physically verified. The size of the tumor is measured using a 
digital caliper. In order to further confirm the pathological condition of the tumor, it is 
excised and sent for immune histology staining. Figure 3-17 (A, B) shows the typical 
H&E staining of tumor tissue at low and high magnifications. Appearance of dark 
granules (hetero chromatin staining) confirms the presence of tumor.  
In order to perform the specificity experiments, three nude mice with tumors are 
injected with PBS, GNR, and GNR-pVIII separately and allowed to circulate for 24 hrs. 
Later, the tumor is excised and immunolabeled with dye labeled anti pVIII antibody. We 
hypothesized phage protein that has specificity to in vitro cells may also be specific in the 
in vivo environment. So, we labeled tumor tissue with rhodamine conjugated antibody 
and DAPI is used as a nuclear counter stain. As expected Figure 3-18 (C) shows the 
tumor is successfully labeled with anti pVIII antibody in GNR-pVIII treated mice where 
as in the controls Figure 3-18 (A,B) no characteristic labeling  is observed. This confirms 
the feasibility of in vivo specificity experiments. The in vivo imaging and photo thermal 
abilities are yet to be examined. 
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Thus, here we developed a new exogenous absorbing agent with phage protein as 
a substitute to antibody. We have previously demonstrated that landscape phage 
displaying VSSTQDFP motifs binds to SKBR-3 cells with high affinity and frequency 
 [179]. Our data also suggested that using multivalent phage libraries considerably 
increases the repertoire of available cell-internalizing ligands with potential applications 
in targeted drug delivery, imaging, molecular monitoring and profiling of breast cancer 
cells. As the affinity selection using phage libraries results in identifying phage and 
peptide ligands that strongly and specifically bind to a target receptor, we hypothesized 
the isolation of major coat proteins from the selected phage should theoretically retains 
the target binding capabilities. On the basis of this hypothesis, we designed and 
synthesized novel GNR-pVIII conjugates know as hybrid nanoprobes by integrating 
phage display technology and nanosynthesis. Our results provide compelling evidence to 
show the feasibility of our new design. Accordingly, when the isolated peptide is 
conjugated onto a photo active substrate such as gold, it can be used for imaging and 
therapy applications. The resulting novel nanomaterial is versatile as any phage protein 
specific to a target cell can be selected and conjugated to functionalized gold nanorods.  
This design confers the target specificity, imaging and destruction of our model SKBR-3 
breast cancer cells.  
Our results show that when SKBR-3 cells are incubated with GNR-pVIII at an 
optical density of 0.5, and a minimum NIR light dose of 0.079 W/cm2 for 5 min with 0.3 
cm spot size is required to destroy viable target cells leaving the control cells unharmed 
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and is in agreement with the previous studies  [170]. The resulting cell death could be 
because of the increase in localized temperature due to thermal effect resulting from the 
accumulation of gold nanorods at the target site. As several earlier studies have discussed 
the optical properties of gold including imaging and its mechanism of action at the target 
site upon NIR radiations  [201] , here we limit our discussion to GNR-pVIII effect at the 
gene level.   
In order to understand the cell biological aspects and the gene expression levels, 
we performed video microscopy and microarray experiments respectively. From our 
video microscopy experiments we can clearly see that the SKBR-3 cells undergo rapid 
membrane ruffling which might indicate the global nature of cellular response mediate 
through cytoskeleton. Interestingly, when SKBR-3 cells are incubated with unmodified 
gold nanorods, we observed most of the cells are withdrawing their membrane ruffling 
towards its center leading to cell shrinkage. However, when cells are incubated with 
protein coated gold nanorods no such behavior is observed. One possible reason for such 
morphological changes observed could be due to the presence of cytotoxic CTAB 
molecules on the surface of gold nanorods. In case of GNR-pVIII conjugate, the surface 
of CTAB is completely modified with polymer and protein decreasing its cytotoxic 
effects on cells.   
Based on our microarray data, we hypothesize GNR-pVIII are binding to heparin-
like gylcosaminoglycans, and activate endocytotic entry pathways predominantly by 
lysosomes. This in turn activates Antigen presentation pathway for their internalization 
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and processing by immunoproteasomes. The expression of few genes from the network 
namely APOE, HLA-A and GAGE-121 were further verified using real time PCR. In 
summary, we hypothesize recognition of GNR-pVIII by cells via heparin-like binding to 
several receptors, including ErbB2, APOE and OLR1, and its internalization via 
endocytotic mechanism. Degradation of GNR-pVIII via lysosomal and proteosomal 
mechanisms was accompanied by activation of immune response utilizing MHC class I 
and G antigen family of genes. Therefore, selective GNR-pVIII entry into target cells 
allows their destruction not only via photoactivation of the nanorods but also by 
recognition of processed peptides by cytotoxic T-cells. Temporal profiling of cellular 
changes in gene expression upon GNR-pVIII exposure will help to answer exact 
sequence of the described events. Our lab is currently investigating the molecular level 
interaction using additional controls such as only gold nanorods, nanorods coated with 
PEG and only phage protein.   
Although, these novel nanomaterials are yet to be optimized for maximum 
efficiency, the ability to control the loading of phage proteins on the surface of 
functionalized nanorods have allowed us to synthesize new nanomaterials that make them 
attractive candidates for medical applications. Similar to the conjugation of 
oligonucleotide on the surface of gold nanoparticles  [202], these novel nanovectors can 
enhance target specificity and allow us to add different functionalities on the nanoparticle 
surface. 
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Chapter 4 : Other Biomedical applications of phage protein and 
genetically engineered filamentous bacteriophage in nanoscience. 
 
4.1 Introduction 
 
Mimicking the controlled assembly of complex biological structures such as 
viruses to modify nanomaterials holds great promise in this new era of molecular 
biomimetics.  Carbon nanotubes (CNTs) continue to receive great attention due to their 
interesting chemical, physical, mechanical and electrical properties. These unique 
properties make them ideal candidates for the development of fuel cells  [203], chemical 
sensors  [204], catalysis  [205], and targeted drug  [206] and gene delivery vehicles 
 [207]. The introduction and delivery of DNA, proteins, or drug molecules into living 
cells is important for therapeutics  [208, 209].  Although some of the existing anticancer 
drugs are very potent, their efficacy is constrained not only by their systemic toxicity and 
narrow therapeutic window, but also as a result of drug resistance and limited cellular 
entry. For this reason, the development of more efficient delivery systems with an ability 
to enhance cellular uptake of existing potent drugs is essential.  
Phage display has being extensively applied to develop nanotechnology  [210], 
leading to the burgeoning of a new branch of science known as phage nanobiotechnology 
 [211]. The filamentous bacteriophage can be genetically modified to display desired 
peptide or the evolutionary phage libraries can be used to select a target binding phage as 
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described in the previous chapter. The filamentous phage such as M13 or fd can be 
simply viewed as the assembly of coat proteins around a circular single-stranded DNA 
(ssDNA) as its genome. During such assembly process, the C-terminal end of the coat 
protein electrostatically interacts with the negatively charged ssDNA. While the N-
terminal end of the coat protein is exposed to the environment and can be fused with a 
foreign peptide such as a cancer cell targeting peptide. Thus, the formation of the 
filamentous phage particle can be simplified as the assembly of pVIII along the ssDNA 
template through non-covalent interactions.  
In this chapter we used three different examples to demonstrate the biomedical 
applications of filamentous bacteriophage. In one, we used the major coat protein of 
screened bacteriophage to demonstrate its assembly on functionalized carbon nanotubes. 
The assembly of virus protein displaying cancer cell receptor binding peptides around 
nanotubes allows the resultant nanoconjugates to bear cell-specific peptides on its surface 
for use in targeted drug and gene delivery and bio-imaging. In the other examples we 
used genetically modified phage as a template for conjugation with photo sensitizer for 
photo dynamic therapy (PDT) applications and for biomimetic assembly of liposomes for 
drug delivery applications. 
In the first example, we used simple layer-by layer self assembly technique for the 
assembly of an oligonucleotide (ss-DNA) and fd bacteriophage major coat proteins onto 
polycationic polyethylenimine (PEI) functionalized multi-walled carbon nanotubes using 
non-covalent interactions. The fd virus major coat proteins used in this study was 
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previously screened using landscape phage libraries and is found to be specific to SKBR-
3 breast cancer cells. We employed Fourier transform infrared spectroscopy, UV-Visible 
spectroscopy, transmission electron microscopy (TEM) and zeta potential analysis to 
confirm the serial assembly process. 
Previous studies show preferential accumulation of photosensitizer in the target 
cancer cells followed by irradiation with appropriate wavelength of light will generate 
cytotoxic singlet oxygen that can eradicate the tumor tissue via apoptosis or necrosis 
 [212]. This method is efficiently used to treat several cancers and other diseases  [212]. 
The current disadvantage in using the photosensitizer is the lack of specificity against 
tumor cells. Hence, in our recent study, the SKBR-3 specific phage described in the 
earlier chapters is conjugated with porphyrin, pyropheophorbid-a (PPa) for the first time 
to form a novel phage-PPa complex  [213]. The complex is characterized by TEM, UV-
visible spectroscopy and the time resolved singlet oxygen measurements. The resulting 
phage-porphyrin complex has potential photodynamic therapy (PDT) application in target 
SKBR-3 breast cancer cells  [213].  
Liposomes are evolved as excellent drug delivery vehicles because of their central 
hydrophilic core and outer hydrophobic compartment  [214]. The entrapment of drugs 
within the inner core makes it isolated from the surrounding environment.  However, its 
gene/drug delivery and PDT applications are limited because of the instability of 
liposomes in biological medium and sensitivity to external environment (temperature and 
osmotic shock). In our study, we used a biomimetic approach to self-assemble the drug 
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loaded liposomes onto filamentous bacteriophage using electrostatic interactions  [215] to 
increase their  stability. As a proof of concept, the filamentous M13 bacteriophage is 
genetically modified to display eight glutamic acid residues and assembled with zinc 
phthalocyanine (ZnPc) loaded cationic liposomes.  The resulting phage-liposome 
complex has potential PDT and drug delivery applications.  
 
4.2 Experiments Performed 
 
4.2.1 Genetic modification of bacteriophage surface with eight glutamic acid 
residues  
Traditional phage display technology was used to introduce eight glutamic acid 
residues (E8) on the N terminus of the major coat protein (pVIII) of M13 bacteriophage. 
In this procedure, an oligonucleotide sequence that codes for eight glutamic acid residues 
is designed. The sequence of forwards and reverse primers is shown below: GLU1 
(forward primer):  
ATCCATGGGAAGAAGAAGAAGAAGAAGAAGAAGATCCCGCAAAAGCG  
GLU2 (reverse primer ): GCAATTTTATCAGCTTGCTTTCGAG  
DNA containing the genes for eight glutamic acids was amplified by using the 
polymerase chain reaction (PCR). Here, we used M13 replicative form (RF) of DNA as 
template and oligonucleotides GLU1 and GLU2 as primers for PCR reaction. Once the 
PCR is completed, the products obtained are purified and isolated. The DNA fragment 
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was digested with Hind III and NCo1 restriction endonucleases and cloned into a 
phagemid that had been previously digested with same restriction enzymes. The 
phagemid permitted the display of eight glutamic acid residues on the N terminus of p8 
protein. The incorporation of the oligonucleotide sequence into the phagemid was 
confirmed by DNA sequencing. 
 
4.2.2 Purification of genetically filamentous bacteriophage  
The SKBR-3 specific bacteriophage was  purified by double polyethylene glycol 
(PEG) precipitation as described previously [216]. Briefly, 40 ml of NZY medium 
containing 20 µg/ml tetracycline was inoculated with a fresh single colony of phage-
infected cells in a 250 ml flask. The culture was incubated under shaking at 370C and 200 
rpm for overnight. Pour the overnight culture in a 250ml Beckman centrifuge bottle and 
centrifuged at 3000 g for 10 min at 4oC. The supernatant was poured into a fresh tube and 
centrifuged at 12000 g for 10 min at 4oC. The resultant cleared supernatant was again 
poured into a fresh tube, to which 6 ml PEG/NaCl solution (100 g PEG 8000, 116.9 g 
NaCl and 475 ml water) was then added. The tube was kept at 40C overnight for phage 
precipitation. The precipitated phages were collected by centrifugation at 31000 g for 15 
min and the supernatant was removed. The pellet was then dissolved in 1 mL Tris 
buffered saline (TBS) in a micro-centrifuge tube and centrifuged again at 12000 g for 2 
min to remove any non dissolved material. 150 μl PEG/NaCl solutions was added to the 
supernatant and kept on ice overnight. The tube was then centrifuged at 12000 g at 4oC 
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for 10 min and the supernatant was removed. The pellet was dissolved in 200 μl double 
distilled water by vortexing. The concentration of phage was estimated using UV-visible 
spectrophotometer by measuring the absorbance at 269nm [217]. The eight glutamic acid 
residue-displayed phage (engineered phage) was obtained by incubating a phage 
suspension with Escherichia coli XL1 blue strain. To obtain the phage suspension, an 
overnight culture of E. coli XL1 blue cells was used. Two tubes of bacterial culture (5 
mL) were incubated with phage in LB medium (1 L) on a shaking incubator at 37 8C. 
The overnight culture was first centrifuged at 2400 g for 10min at 4 8C with a Beckman 
Coulter high performance centrifuge, and the supernatant was collected and recentrifuged 
at 6700 g for 10 min at 4 8C. Then a solution of PEG and NaCl was added and the 
suspension was stored in refrigerator. 
 
4.2.3 Purification of SKBR-3 specific phage protein  
SKBR-3 targeting phage selected from f8/8 landscpe library is solubilized as 
described by  [218]. The major coat protein was isolated as described in earlier chapter.  
Briefly, 5 ml of purified phage solution (1x 1014 virions/ml) was mixed with 10ml of 
120mM cholate in 10mM Tris-HCl, 0.2mM EDTA, pH 8.0, and chloroform( 2.5% v/v). 
The mixture was incubated for 1h at 37OC with occasional stirring. The dissociated phage 
was then applied to a sepharose column and eluted with 10mM cholate in 10mM Tris-
HCl/0.2 mM EDTA, pH 8.0, to separate the major coat proteins from the phage DNA. 
The various fractions at 1ml each was then collected and analyzed using a UV-Visible 
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nanophotometer. Fractions with an absorbance ratio of A280/A260 greater than 1.5 were 
stored at 4oC for further use. The protein concentration was estimated using a Bradford 
assay and the purified protein was confirmed using 15% SDS-PAGE electrophoresis and 
western blotting.  
 
4.2.4 Carbon nanotube functionalization with SKBR-3 specific coat protein  
Pristine multiwalled CNT (length 15µm and diameter 20-60nm) were purchased 
from Carbon Nanotechnologies Incorporation (CNI). All chemicals were of analytical 
grade and used as received. The surface modification of carbon nanotubes was performed 
using the following procedure  [219].  First, 10mg of multi walled carbon nanotube 
(MWNTs) powder was treated with 10 ml of concentrated sulfuric acid/nitric acid 
mixture (3/1 in v/v) under strong sonication for 10 hr. After this treatment, the oxidized 
MWNTs were obtained after filtration and were then thoroughly rinsed. Subsequently, 
the pH was adjusted to 7 in order to achieve net negatively charged carboxylate groups. 
For typical functionalization with PEI, oxidized MWNTs (0.5 mg mL-1) were mixed with 
polycationic polyethylenimine (PEI) (2 mg ml-1) under ultra-sonication for 1hr 
immediately followed by 30 min of vigorous vortexing. The mixture was centrifuged at 
10,000 rpm for 25 min and the pellets were collected and redispersed in 5mL of 
deionized water. This centrifugation/wash/redispersion cycle was further repeated twice 
to remove any physically absorbed polymer and free polymer attached to the carbon 
nanotubes. Finally, the polymer-MWNTs composite was redispersed in water. Later PEI 
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was used as a linker to adsorb anionic ss-DNA. The ss-DNA (OD 20) was mixed with 
5ml of MWNT conjugated PEI and vortexed for 30 min. After vortexing the mixture was 
treated with a series of centrifugation / wash / dispersion /centrifuge/redispersion cycles, 
and finally the MWNT@PEI/ssDNA conjugate was obtained.  The pVIII (1.03 mg/ml) 
solution was mixed with 5ml of MWNTs@PEI/ssDNA conjugate dispersion and 
vortexed for 30min. The resultant pellet was collected after centrifugation and 
purification. Finally the MWNTs@PEI/ssDNA/pVIII was dissolved in 0.5x PBS. 
 
4.2.5 Conjugation of SKBR-3 specific bacteriophage with photosensitizer, PPa  
In this procedure, first 1 mg of PPa was dissolved in 1 mL of DMSO and the 
carboxyl groups are activated with 0.4 mg EDC.  The reaction mixture was incubated at 
37oC on a shaker for 1hr and after incubation; the unreacted EDC was quenched by few 2 
μl of mercapto ethanol (MeSH). The resultant activated PPa was stored at -80oC for 
further use. The modification of bacteriophage with PPa was performed by carefully 
adjusting molar ratio between the two. In order to retain the target specificity of the 
resulting phage, the phage is partially modified with PPa. Briefly, 22.5μl of activated PPa 
was added to 2ml of phage solution (6.4x1012 virons/ml). The mixture is incubated for 
1h at 37oC under constant shaking. The free dye is removed using extensive dialysis 
against distilled water. The solutions are stored at -200C for further use. 
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4.2.6 Assembly of cationic liposomes on glutamic acid displayed bacteriophage :    
  Lipid 1,2-dioleoyl-3- trimethylammonium propane chloride (DOTAP) and 1,2-
dioleoyl-sn-glycerophosphocholine (DOPC) were obtained as chloroform solutions from 
Avanthi lipids. Later the cationic liposomes were prepared from 1,2-dioleoyl-3- 
trimethylammonium propane chloride (DOTAP) and 1,2-dioleoyl-sn-
glycerophosphocholine (DOPC) in a mass ratio of 30:70 in the presence of CTAB as a 
surfactant by using the detergent depletion method  [220]. A stock solution of ZnPc was 
dissolved in N-methyl-2-pyrrolidinone at 500C and added to the chloroform mixture of 
DOTAP/DOPC such that the ratio of ZnPc/lipid was kept constant at 1:100. The ZnPc/ 
lipid solution was dried with a stream of nitrogen gas and a transparent film was 
deposited in the bottom of a glass vessel. A highly concentrated solution of CTAB (3:1 
detergent/lipid molar ratio), prepared with a phosphate buffer (10mM NaH2PO4, pH 7.0; 
100mM NaCl), was added to the dried film. Samples were then sonicated until clear to 
form mixed micelles, and extensive dialysis was performed with a dialysis bag 
(molecular weight cutoff 6–8000) with three changes of phosphate buffer solution. After 
dialysis, residual CTAB was removed from the liposome mixture by eluting the 
suspension through a Sephadex G-50 column with the same solvent. The resultant 
liposome solution was filtered by extrusion through a polycarbonate membrane with 200-
nm pores (Avestin, Ottawa, Canada) to remove ZnPc that was not incorporated in the 
lipid bilayer of the liposomes. The assembly of liposomes on the phage to form phage–
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liposome complexes was initiated by adding an aliquot of phage to a solution of the 
liposome. 
 
4.2.7 Transmission electron microscopic studies  
The surface morphology of carbon nanotubes after polymer coating and protein 
coating was verified using TEM. The morphological differences between the SKBR-3 
specific phage before and after modification with PPa was examined using high 
resolution TEM. Also, the assembly of liposomes on glutamic acid residues displayed 
phage is verified using TEM. The various functionalized carbon nanotubes samples are 
dropped on a copper grid and viewed under TEM. In case of porphyrin modified phage, 
solution was dropped on a Tedpella carbon coated silver grids and stained with uranium 
acetate for 10 sec.  All TEM images were recorded at the same magnification to 
understand the morphological changes using JEOL 2000 FX. In case of phage-liposome 
complex, the phage was stained with 1.5% uranyl acetate (pH 3.5), and the phage–
liposome complex was stained with a neutral solution  containing 2.5% phosphotungstic 
acid and 1.5% trehalose and viewed under Zeiss 10 TEM. 
 
4.2.8 Singlet oxygen measurements using steady state method  
In order to demonstrate the ability of phage-PPa complex to produce singlet oxygen 
necessary for PDT experiments, we performed steady state method to confirm the 
generation of singlet oxygen. Here  we used 1,3-diphenylisobenzofuran (DPBF), as a 
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standard singlet oxygen 1O2 trap  [221] in dimethyl sulphoxide (DMSO) and excited with 
658±10 nm of continuous wave laser. In these steady state experiments, the absorption of 
PPa and p-PPPa at 658nm was fixed to 0.1. All the experiments were carried out in an air 
saturated DMSO solution using picomolar concentrations of DPBF at ambient 
temperatures of 20-22oC in completely dark conditions. Samples were photolyzed in a 1 
cm quartz cell with a 658 nm diode laser (using continuous laser) at 50 mW of power. 
The disappearance of DPBF was monitored at: 0, 15, 45, 75, 105, 135, and 165 seconds 
by its change in absorbance at 410 nm.  
 
4.2.9 Cell culture, functionalized nanotubes incubation and fluorescence microscopy  
The target SKBR-3 breast cancer cells and the control MCF-7 cells were cultured 
in Mc. Coy’s and DMEM medium supplemented with penicillin (100 μg /mL), 
streptomycin (100 μg/mL), and 10% heat-inactivated FBS. Both the target and control 
cells were incubated with MWNT@PEI and MWNT@PEI/ssDNA/pVIII (the DNA here 
is fluorescently labeled with fluorescein isothiocyanate (FITC)) conjugates at a 
concentration of 10μg/mL and allowed to interact for 1hr. After incubation, the medium 
was removed and the cells were washed thoroughly three times to remove non-specific 
interactions between the carbon nanotubes and cells. All the target and control cells were 
examined under a Zeiss Universal epiflourescence microscope equipped with Olympus 
oil immersion DApo UV objectives. Digital images of the cells were collected using the 
Olympus DP-70 camera and software. 
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4.2.10 In Vitro Photo dynamic therapy (PDT) studies  
The target SKBR-3 cells and control MCF-7 cells were cultured in a six well plate 
till they reached 90% confluence as described above. Then a 10 μM concentration of 
porphyrin and phage coated porphyrin were prepared in suitable medium and incubated 
with target and control cells for 1 h at 37oC. After 1h of incubation, the unbound 
conjugates are removed by through washings with PBS and the finally replaced with 
fresh medium. For PDT experiments, 7.5 J/cm2 of illumination was delivered using a 
visible green laser light. The light spot covered four wells, which were considered as one 
experimental group illuminated at the same time. Control groups involved cells without 
conjugates, treated with laser light alone, treated with bacteriophage without prophyrin 
complex and with porphyrin alone (absorption at 685 nm is 0.1). For time course 
incubation studies the phage coated porphyrin were incubated with SKBR-3 cells and 
MCF-7 cells for various times (1h, 15h and 24h) and subsequently PDT with 7.5 J/cm2 of 
658 nm light was delivered at dose of 50 mW/cm2. Following PDT treatment the cells 
were returned to the incubator for few hours and a live/dead cell viability kit is used to 
evaluate the cell death. All the fluorescence images were captured using Nikon Eclipse Ti 
system. 
 
4.3 Results 
4.3.1 Self assembly of coat proteins on functionalized carbon nanotubes 
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  In our biomimetic protein self assembly procedure (as shown in Figure 4-1), the 
MWNTs were first oxidized with a sulphuric acid mixture and modified with 
polycationic PEI polymer. The functionalized nanotubes were further wrapped with 
negatively charged ssDNA and then coated with pVIII specific to SKBR-3 cells by 
mimicking the phage assembly process where several thousand copies of pVIII are 
assembled along ssDNA to form a mature phage particle (as shown in Figure 1-3). The 
initial surface modifications were characterized by FT-IR as shown in Figure 4-2.  A 
broad band is found at 3420 cm-1 for the oxidized MWNT which is attributed to the 
presence of –OH groups. The peaks at 1712 and 1624 cm-1 correspond to carboxylic 
groups and carbonyl groups, respectively. The coating of PEI on MWNTs was also 
characterized by FT-IR spectra, which show double peaks within 2800-2900 cm-1 
assignable to the –CH2- group (Figure 4-2). Later ssDNA was added to the MWNT@PEI 
composite, resulting in a MWNT@PEI/ssDNA conjugate. Figure 4-3 shows the UV-
visible spectra of the MWNTs, MWNT@PEI and MWNT@PEI/ssDNA suspension. The 
MWNT@PEI composite exhibited the same characteristic peak found for PEI, suggesting 
that PEI is attached to the MWNT surface. On the other hand, the purified 
MWNT@PEI/ssDNA composite showed small peaks at 260 nm, which was also found to 
be the characteristic peak from ssDNA, suggesting that ssDNA is attached to the surface. 
We further performed zeta potential measurements to determine the surface charge of 
functionalized nanotubes as shown in Figure 4-4. MWNTs are negatively charged at pH 7 
which is consistent with the Zeta potential value of -23.84 mV. This suggests a 
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deprotonation of the functional carboxylic groups on the MWNTs surface after 
modification with the sulfuric acid/nitric acid mixture. After functionalization with the 
polycationic PEI coating, the surface charge turned positive, suggesting that the 
outermost layer is a polycation. This implies a successful coating of the polymer on the 
MWNTs. The oligonucleotide coating on the MWNTs surfaces was expected to have a 
change in polarity and zeta potential values. As expected, the zeta potential of the 
resultant dispersion is negative, indicating that the ssDNA was successfully coated onto 
the surface. Further, when the pVIII solution was added to the MWNTs@PEI/ssDNA 
conjugate dispersion and vortexed for 30min, the zeta potential of the suspension is 
changed but still negative upon the assembly of pVIII onto the MWNTs@PEI/ssDNA 
conjugate. The pVIII-terminated surface showed a negative surface charge, indicating 
that the positively charged C-terminal domain of pVIII was in contact with the 
negatively-charged ssDNA surface via electrostatic interactions, as in the case of phage 
assembly  [218]. As a result, the slightly negative N-terminal domain of the same pVIII, 
to which cell-targeting peptides are fused, is extended outside, enabling the targeting of 
the nanotubes to cancer cells. The successful functionalization of MWNTs resulted in 
remarkably increased water solubility, providing stability for longer times in aqueous 
solutions (Figure 4-5). 
The increase in thickness of polymer and protein on carbon nanotubes surface 
were further evaluated using TEM (as shown in Figure 4-6 & 4-7). Figure 4-6 shows a 
typical lattice structure of unmodified MWNTs. Upon coating with PEI, the MWNTs 
140 
 
resulted in the appearance of an amorphous layer having a thickness of approximately 2 
nm covered on the MWNT surface (Figure 4-7 B). When a solution of MWNTs@PEI in 
aqueous suspension was mixed with ssDNA, a further increase in the thickness of the 
amorphous coat was observed as shown in Figure 4-7 C, this could be resulting from the 
interactions of ssDNA and positively charged groups on the nanotubes. The degree of 
condensation of ssDNA on nanotubes depended mainly on the charge density and number 
of ssDNA molecules.  [222] Finally, the SKBR-3 cell-specific pVIII, which bears 
positively charged amino acids on the C-terminus, was electrostatically interacted with 
ssDNA functionalized MWNTs. This resulted  in an increase in the average surface 
thickness by approximately 1 nm (Figure 4-7 D), which is in agreement with the length of 
pVIII proteins (the major coat protein is composed of 50 amino acids),  [223] suggesting 
the formation of a monolayer of pVIII on functionalized MWNTs/ssDNA. 
In order to demonstrate the in vitro applications of carbon nanotubes coated with 
cell-targeting phage-derived coat proteins for targeted delivery applications, we studied 
their interactions with target breast cancer cells (SKBR-3) cells and control cells (MCF-7 
cells). For this application purpose the nanotubes were functionalized with fluorescent 
DNA. Therefore, the functionalized carbon nanotubes were first wrapped with 
fluorescein conjugated DNA and then conjugated with SKBR-3 specific pVIII. As 
expected, no fluorescence was observed in the SKBR-3 cells treated with MWNT@PEI 
due to a lack of chromophore on the polymer. However, the SKBR-3 cells treated with 
MWNT@PEI/ss-DNA/pVIII showed obvious green fluorescence from the DNA (Figure 
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clearly observe a change in the morphology of filamentous bacteriophage before and after 
photo sensitizer modification. From the TEM images the structure of unmodified 
bacteriophage seems to be flexible (as shown in Figure 4-9A) in structure and upon 
completely coating with PPa, the phage is straightened and rigid (as shown in Figure 4-
9B). Production of singlet oxygen is the most important aspect of PDT experiments. 
Hence, we used steady state method to understand the photo physical properties of phage 
coated porphyrin complex. A decrease in DPBF absorption at 410 nm confirmed the 
formation of DPBFO2 by its reaction with 1O2 produced from photolysis (Figure 4-10). 
We estimated the amount of 1O2 molecules produced in both PPa and p-PPPa by 
calculating the concentration of DPBFO2 formed (Figure 4-11). Kinetic calculation 
confirmed that the concentration of DPBF was sufficient to intercept more than 95% of 
the 1O2 produced in the solution.  
In order to understand the photodynamic therapy efficiency of phage-porphyrin 
complex we performed in vitro evaluation on target and control cells. As shown in Figure 
4-12, target SKBR-3 cells treated with phage-PPa complex were found to be dead ( 
stained by ethidium bromide in red) upon laser irradiation and control MCF-7 cells were 
not dead (stained by calsein AM in green) by phage-PPa complex. This confirms the 
specificity of our phage towards the target cells. However, in presence of porphyrin alone 
both the target and control cells were found dead. These results clearly demonstrate that 
our novel p-PPPa sensitizer with inherent target specific phage selectively kills SKBR3 
cells upon irradiation with 658 nm laser light. 
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surface is electrostatic interactions. Because, the phage protein present on the nanotube 
surface show specificity to target SKBR-3 breast cancer cells, we expected the 
fluorescently labeled DNA present on the nanotubes binds to the desired cells. As 
expected no significant binding is noticed in the control MCF-7 cells. In principle, we 
believe the structure of protein-nanotubes formed here can be regulated by modifying the 
different bases in the oligonucleotide sequence or by the number of oligonucleotide 
chains grafted onto the nanotube surface. Thus, the results presented here show the 
synthesis of multicomponent assemblies resulting from oligonucleotide and protein 
conjugation for biomedical applications. 
The bacteriophage morphology is an important aspect for retaining the binding 
properties with targeted cells. When the bacteriophage surface is partially modified with 
photosensitizer, no significant morphological changes are observed but when the phage is 
completely modified with porphyrin, they became straightened and rigid. This major 
morphological change could be due to the strong hydrophobic interactions between the 
phage major coat proteins and the PPa macrocycle. 
In cancer PDT, upon irradiation with light, excited singlet oxygen (1O2) is 
generated to induce the killing of cancer cells.[32] Thus, we investigated the efficiency of 
using phage–porphyrin complexes for cancer PDT by measuring the production of 
excited singlet oxygen (1O2) and also by imaging breast cancer cells after their interaction 
with the phage-PPA complexes for 1 h. The activity of Phage-PPa for the production of 
1O2 was studied by following time resolved experiments as discussed earlier. Target and 
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control cells were treated with porphyrin and phage-porphyrin complex separately and 
irradiated with a laser power density of 50 mW/cm2 for a period of 4 minutes. The laser 
power used in our study is much lower than the power generally used in PDT 
experiments (200mW/cm2). This study highlights the new class of virus enabled PDT 
photosensitizers for targeted cancer treatment.  Further evidence showing the mechanism 
of cell death is under current investigation. 
The electrostatic interaction between the anionic phage and cationic liposomes 
resulted in the self-assembly and immobilization of liposomes on the phage to form a 
phage–liposome complex. The self-assembled phage–liposome complex can not only 
stabilize the liposomes against flocculation and but also help in the delivery of drug-
loaded liposomes to specific targets (Example: cancer cells). Also, when a cationic 
electron acceptor such as methyl viologen ions are electrostatically immobilized on the 
sidewall, it results in desired charge separation in electron-transfer reactions between the 
dye in the liposomes and the immobilized electron acceptor on the phage. 
In summary, we have studied the morphological control of nanomaterial assembly 
on filamentous bacteriophage and evaluated their chemical and biological properties for 
possible applications in imaging, PDT and drug delivery. Thus by exploiting the 
multivalent nature of the phage and its rigidity, we can assemble novel virus-based 
nanostructures that can be used to various biomedical applications. 
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Chapter 5  
 
5.1 Summary of this dissertation 
 
Cancer continues to be the leading disease causing killer in the United States. 
Development of more efficient methods for the simultaneous imaging and selective 
destruction of cancer is currently an active field of research. The well defined geometries, 
surface functionalities and monodisperse nature of viruses make them an ideal candidate 
for phage display technology and nanofabrication.  With the recent advancement in 
nanotechnology and the applications of phage display technology, it is now possible to 
combine both on a single platform for potential biomedical applications. This new 
approach of cancer treatment integrates the target specific binding and circulatory 
behavior of viruses and nanosize architecture with unique optical properties for effective 
molecular interactions and novel practical applications.  
  The first part of this dissertation is aimed at exploring unique protein-protein 
interactions between the target SKBR-3 breast cancer cells and landscape phage libraries. 
Here we identified new cell targeting/internalizing peptides (and the phages with such 
peptides fused to each of ~3900 copies of their major coat protein) using landscape phage 
libraries and for the first time investigated the actin dynamics when selected phages are 
internalized into the SKBR-3 breast cancer cells. Our results show that phages harboring 
VSSTQDFP and DGSIPWST peptides could selectively internalize into the SKBR-3 
breast cancer cells with high affinity, and specificity. The actin dynamics was studied by 
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using live cell and fluorescence imaging. The cell-internalizing phages were found to 
enter breast cancer cells through energy dependent mechanism; and phage entry 
interferes with actin dynamics, resulting in reorganization of actin filaments and 
increased membrane rufflings in SKBR-3 cells. These results suggest that, when phage 
enters epithelial cells, it triggers transient changes in the host cell actin cytoskeleton. This 
study also shows that using multivalent phage libraries considerably increases the 
repertoire of available cell-internalizing ligands with potential applications in targeted 
drug delivery, imaging, molecular monitoring and profiling of breast cancer cells. 
With the recent progress in nanotechnology it is now possible to custom 
synthesize a variety of nanomaterials for biological applications. In particular gold 
nanorods has been of great interest to researchers in cancer because of their easy 
preparation, ability for bioconjugation, excellent biocompatibility, tunable and enhanced 
scattering and absorption properties. The strong scattering and absorption from gold 
nanorods provides an opportunity for their use in cancer cell imaging and photo thermal 
therapy applications.  
The second part of this dissertation is aimed at the synthesis, multipurpose 
applications, and molecular level interactions of novel nanoprobes. Here, we demonstrate 
the first example of the self-assembly of coat protein pVIII derived from filamentous 
phage onto gold nanorods to form GNR-pVIII complex (nanoprobe). The 
biocompatibility, specificity, imaging and photo thermal abilities of GNR-pVIII were 
demonstrated using various spectroscopic and microscopic techniques. Our results show 
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that phage coat proteins enable the tumor-specific targeting and internalization of 
nanoparticles to target cells. Further, gene expression profiling using microarrays 
identified the novel mechanism of the interaction between GNR-pVIII and target breast 
cancer cells. We hypothesize GNR-pVIII were first bound to heparin on the cell surface 
and then internalized by lysosomes. Due to the structural similarity of GNR-pVIII with 
phage, the coat proteins on the GNRs might be interacted with the Major 
Histocompatibility Complex I (MHC class I), and transported to immune system for 
destruction, leaving gold nanorods inside the cells. Furthermore, seven members of the 
poorly annotated G antigen family (GAGE) genes were activated by GNR-pVIII 
complex, possibly representing novel mechanisms of GNR-pVIII processing by immune 
system. Thus mimicking phage structure to develop novel nanoprobes opens up a new 
way to develop targeted therapeutics. In conclusion, GNR-pVIII exhibited excellent 
multi-functional properties including target specificity, non-cytotoxicity, as well as 
imaging and photo thermal destruction capability in our model SKBR-3 breast cancer 
cells. 
The third part of this dissertation is aimed at exploring the filamentous structure 
and proteins components of bacteriophage for novel biomedical applications.  Here, three 
different examples are used to prove the biomedical applications of bacteriophage. In the 
first example, we demonstrate the conjugation of coat proteins on functionalized multi 
walled nanotubes for targeted delivery. Here, we report a simple layer-by layer self 
assembly technique for the assembly of an oligonucleotide (ss-DNA) and fd 
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bacteriophage major coat proteins onto polycationic polyethylenimine (PEI) 
functionalized multi-walled carbon nanotubes using non-covalent interactions. The use of 
various spectroscopic and microscopic techniques confirmed the assembly of coat 
proteins on functionalized nanotubes. The resulting nanocomposites may find potential 
applications in drug/gene delivery, medical therapy, and bioanalytical sensing. 
In the second example we report the first conjugation of porphyrin, 
pyropheophorbid-a (PPa), to SKBR-3 specific bacteriophage (L1 phage), to form a novel 
phage-PPa complex and its successful in vitro PDT application in targeting SKBR-3 
breast cancer cells. The resulting complexes were characterized by various spectroscopic 
and microscopic techniques. The incubation of phage-PPa complex with target SKBR-3 
cells for 1h and irradiation with 7.5 J/cm2 red laser at 658nm resulted in the death of 
target cancer cells leaving the control cells unharmed. Thus, the reported virus enabled 
photosensitizers open new avenues for novel photosensitizers for clinical applications. 
In the third example, a biomimetic approach is used to stabilize the drug loaded 
liposomes via the self-assembly of ZnPc-loaded liposomes on the glutamic acid 
engineered bacteriophage. The resultant composites can be used for PDT (if the 
liposomes are entrapped with a photosensitizer) and drug-delivery applications (if the 
liposomes are entrapped with a chemotherapeutic agent). Here, M13 phage was 
genetically modified to display a negatively charged peptide (eight glutamic acid 
residues) on the sidewall of 2700 copies of ordered major coat protein pVIII which 
allowed strong multivalent electrostatic interactions with the cationic liposomes. The 
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electrostatic interaction between the anionic phage and cationic liposomes resulted in the 
self-assembly and immobilization of liposomes on the phage to form a phage–liposome 
complex and characterized by using electron microscopic imaging. The resulting self-
assembled phage–liposome complex can not only stabilize the liposomes against 
flocculation but might also help in the delivery of drug-loaded liposomes to specific 
targets. 
In conclusion, genetically engineered nanoconstructs derived from phage 
components and nanomaterials can be envisioned as novel probes for biomedical 
applications. A variety of novel nanoassembled structures are currently under 
investigation in which bacteriophage is being an active ingredient because of their 
interesting characteristics features such as monodispersity, characteristic surface 
properties, and error free production. Despite extensive research in utilizing genetically 
engineered nanoconstructs for medical applications, there is still concern regarding their 
toxicity. At present the great challenges in front of researcher are to successfully 
overcome the toxicity, immunogenicity of the hybrid system and to increase the 
therapeutic efficiency at the target site. Overall, genetically engineered nanoconstructs 
are showing tremendous advancement in many fields of research indicating great 
potential for applications in the future. 
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